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Many human breast cancers overexpress the E3 ubiquitin ligase MDM2 and its homolog 
MDMX. Expression of MDM2 and MDMX occurs in both estrogen receptor α positive (ER+) 
and triple negative breast cancer (TNBC). We and others have reported that estrogen activated 
MDM2 strongly promotes proliferation in ER+ T47D breast cancer cells in a p53-independent 
manner. Whether MDM2 elicits in vivo p53-independent proliferative functions in T47D breast 
cancer cells has not been determined. Furthermore it has been shown that ectopic expression of 
MDM2 targets E-Cadherin for degradation thus leading to increased cell migration and invasion. 
Therefore we assessed the in vivo function of MDM2 in an ER+ mtp53 (L194F) expressing 
T47D orthotopic mouse model and demonstrated that MDM2 knockdown considerably 
attenuated primary tumor growth. However depletion of MDM2 did not reduce tumor 
invasiveness and failed to increase E-Cadherin levels. Conversely in mtp53 (R280K) expressing 
MDA-MB-231 cells, which belong to claudin-low/TNBC subtype, inducible MDM2 knockdown 
reduced migration without changing cell proliferation. This indicates a context dependent role of 
MDM2 in breast cancer progression. Co-overexpression of mdm2 and mdmx has been 
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documented in the Claudin-low/TNBC subtype, and high levels of MDMX in TNBC cell lines 
confer tumorigenic functions. Therefore we generated constitutive MDM2 or MDMX 
knockdown cell lines that could be tracked by GFP expression to compare their biological 
outcomes in proliferation, migration and in vivo metastatic potential. While MDMX knockdown 
showed a decreased tumor volume in NSG mice at the early stage of tumor development, MDM2 
knockdown did not change tumor size. Importantly MDM2 or MDMX knockdown significantly 
reduced the number of circulating tumor cells (CTCs) and lung foci formation. To explore the 
molecular targets of MDM2 and MDMX, we carried out qRT-PCR tumor metastasis array card 
screening with cDNA from primary tumors. Subsequent validation identified MDMX down-
regulation in MDA-MB-231 orthotopic tumors correlated with a significant decrease in cxcr4 
transcript and a trend of reduction for ptgs2 transcript. To determine if cxcr4 and ptgs2 were 
directly upregulated by MDMX, we assessed their transcript levels upon MDMX knockdown in 
two-dimensional cultured cells and observed no association between MDMX, cxcr4 and ptgs2. 
This suggests MDMX is involved in indirect regulation of cxcr4 only in the tumor 
microenvironment. Our data positions MDM2 and MDMX as context specific regulators in 
breast cancer development and highlights the importance in considering their differential 
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1.1.1 Discovery and transcriptional regulation of MDM2 
The mdm2 gene was first discovered in 1987 in the 3T3DM spontaneously transformed 
mouse fibroblast cell line due to genomic amplification on double minute chromosomes (Cahilly-
Snyder et al., 1987). Forced overexpression of mdm2 in NIH3T3 cells induces tumorigenicity 
when introduced in nude mice, confirming mdm2 as an oncogene (Fakharzadeh et al., 1991).  It 
was then discovered to be essential in embryogenesis as deletion of MDM2 results in mouse 
embryonic lethality owing to apoptosis induced by tumor suppressor p53. This lethal phenotype 
can be rescued by concomitant deletion of p53, highlighting MDM2 as a central regulator of p53 
during development (Jones et al., 1995; Montes de Oca Luna et al., 1995).  
The human mdm2 gene is located on chromosome 12 (cytogenetic band: 12q15) and is 
approximately 33 kb (Iwakuma and Lozano, 2003; Oliner et al., 1992). The full-length transcript 
of mdm2 consists of 12 exons and the transcription of mdm2 is driven by two promoters (Barak et 
al., 1994; Fakharzadeh et al., 1991). The P1 promoter, located upstream of exon 1, controls basal 
levels of mdm2 expression. The P2 stress–dependent promoter, located in intron 1, contains 
regulatory motifs for various transcription factors that allow it to be transcriptionally up-regulated 
in response to many signaling pathways (reviewed in (Manfredi, 2010)). A variety of transcription 
factors have been shown to induce the expression of MDM2 including p53 (Zauberman et al., 
1995), AP-1/Ets family (Phelps et al., 2003), SMADs (Araki et al., 2010), MYCN (Slack et al., 
2005) and estrogen receptor (ER) (Kinyamu and Archer, 2003).  
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1.1.2 Alternative splicing of mdm2 
MDM2 is also subject to aberrant and/or alternative splicing (Bartel et al., 2002). More 
than 70 different mdm2 splice variants have been identified in normal tissue and tumors (reviewed 
in (Okoro et al., 2012)). Among the detected transcripts variants, mdm2-a, mdm2-b, mdm2-c, 
mdm2-d, and mdm2-e are documented in tumor tissue samples and a variety of cancer cell lines. 
Furthermore, these splice variants are able to form in-vitro translated protein suggesting potential 
biological functions in cancers (Sigalas et al., 1996). The most studied splice variants mdm2-a, 
mdm2-b, and mdm2-c, are missing exons encoding the p53 binding domain, the nuclear 
localization and export sequences, and the acidic domain (Okoro et al., 2012). Mdm2-a (which 
lacks exons 4-10) overexpression has been shown to increase cellular transformation in p53-null 
MEFs and alter the tumor spectrum in transgenic mice, suggesting a p53-independent oncogenic 
activity of this protein (Volk et al., 2009). Mdm2-b is the smallest splice isoform documented to 
date. The protein isoform is a result of translation from exon 3 and exon 12. Tissue-restricted 
expression of mdm2-b results in an increased tumorigenesis independently of p53 (Steinman et al., 
2004). Ubiquitous expression of mdm2-b in the absence of p53 causes an accelerated tumor 
formation and an altered tumor spectrum, with high incidence of rhabdomyosarcoma in transgenic 
mice (Comiskey et al., 2018), highlighting the importance of mdm2-b in cancer development. We 
have previously shown that mdm2-c transcript can form endogenous MDM2-C protein in a 
variety of cancer cell lines and tissues. This protein isoform has p53-independent transforming 
potentials when overexpressed (Okoro et al., 2013). Therefore it is important to take into 
consideration how these endogenous isoforms contribute to cancer in order to better understand 
how MDM2 functions. 
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1.1.3 MDM2 protein structure and interacting partners  
The full length mdm2 transcript encodes a 491 amino acid protein product with a 
calculated molecular weight of 54 kDa. It is roughly divided into N-terminal, Central region and 
C-terminal domains (Figure 1) (Chen et al., 1993; Fakharzadeh et al., 1991). 
 
Figure 1. Schematic representation of full-length MDM2 protein structure.  
The Full-length MDM2 protein with functional domain depicted. The N-terminus contains p53-
binding domain and a putative SWIB domain. The central region consists of nuclear localization 
signal (NLS), nuclear export signal (NES), acidic domain and zinc finger domain. This is 
followed by the RING finger domain and nucleolar localization signal (NoLS) at the C-terminus. 
The exon encoding corresponding portion of MDM2 is shown on top. Modified from (Okoro et 
al., 2012). 
 
The amino terminal domain consists of a hydrophobic cleft that is essential in interacting 
with and inhibiting p53 transcriptional activity (Chen et al., 1993). Additionally the SWIB 
domain of MDM2 resembles that of chromatin remodeling complex SWI/SNF (Bennett-Lovsey et 
al., 2002), suggesting a chromatin remodeling function of MDM2. A number of proteins have 
been reported to interact with MDM2 via its N-terminus such as p53 (Chen et al., 1993; Kussie et 
al., 1996), p300 (Grossman et al., 1998; Kobet et al., 2000), E2F1/DP1 (Martin et al., 1995) and 
Notch1 (Pettersson et al., 2013).  
The central region of MDM2 includes a linker region with nuclear export and localization 
signals (NES and NLS), an acidic domain and a zinc finger domain. The NES and NLS are 
responsible for MDM2 nucleo-cytoplasmic shuttling (Roth et al., 1998). The acidic domain 
interacts with the DNA-binding domain of p53 and is necessary for MDM2-mediated p53 
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ubiquitination (Ma et al., 2006; Wallace et al., 2006). Several ribosomal proteins (L5, L11, L23, 
L26) bind to MDM2 via acidic and zinc finger domain to promote p53 stabilization and activation 
(reviewed in (Liu et al., 2016)). In addition to p53, MDM2 also interacts with p21, RB and 
Mre11/Rad50/Nbs1 (MRN) repair complex through the acidic domain (Alt et al., 2005; Sdek et 
al., 2004; Zhang et al., 2004). 
The carboxyl terminus contains the RING finger domain that determines the E3 ubiquitin 
ligase activity of MDM2 towards many substrates including p53, MDMX and MDM2 itself (Fang 
et al., 2000; Honda et al., 1997; Pan and Chen, 2003). The extreme C-terminal tail of MDMX and 
MDM2 are critical for their heterodimerization and trans-ubiquitination (Linke et al., 2008; 
Uldrijan et al., 2007). A cryptic nucleolar localization signal (NoLS) within the RING domain has 
been shown to cooperate with the NoLS in p14ARF and allows for relocalization of both proteins 
(Lohrum et al., 2000). It is noteworthy that besides the E3 ligase function, MDM2 has been 
shown to bind to tp53, xiap, slug, and mycn transcripts via the RING finger domain (Gu et al., 
2012; Gu et al., 2009; Jung et al., 2013)(summarized in (Fahraeus and Olivares-Illana, 2014)).  
1.1.4 The MDM2-p53 regulation loop 
p53 induces the transcription of mdm2 by binding to the response elements located near 
the mdm2 P2 promoter (Barak et al., 1993; Juven et al., 1993; Zauberman et al., 1995). The 
resulting MDM2 protein in turn, confers multifaceted functions in regulating p53 activity, cellular 
localization, protein synthesis and stability thus forming an autoregulatory feedback loop with 
p53. 
As an E3 ligase, the core function of MDM2 is to ubiquitinate p53 for rapid degradation 
though the 26S proteasome (Fang et al., 2000; Haupt et al., 1997; Honda et al., 1997; Kubbutat et 
al., 1997; Xirodimas et al., 2001; Yu et al., 2000). Interestingly the monoubiquitination of p53 by 
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low levels of MDM2 is sufficient to induce cytoplasmic translocation (Li et al., 2003; Lohrum et 
al., 2001), demonstrating a fine-tuned control of p53 by MDM2. In addition to regulating p53 
stability and protein trafficking, MDM2 also suppresses p53 transcriptional activity by binding to 
its N-terminus (Momand et al., 1992; Thut et al., 1997). Early studies identified the core p53-
binding domain in the MDM2 N-terminus to be sufficient for the inhibition of p53 transactivation 
(Momand et al., 1992). Pharmacological inhibitors such as Nutlin-3, which disrupts N-terminal 
associated MDM2-p53 interactions, can reactivate the p53 pathway in many types of cancer 
(Tovar et al., 2006; Vassilev et al., 2004). Moreover it has been reported that the acidic domain of 
MDM2 blocks p53 DNA-binding and induces p53 conformational change (Cross et al., 2011), 
providing multiple mechanisms by which MDM2 inhibits p53 transactivation. Finally the 
regulation of p53 protein synthesis by MDM2 is also dynamic and context specific. MDM2 
targets RPL26, a ribosomal protein that boosts p53 translation by binding to its mRNA, for 
polyubiquitination and proteasomal degradation (Ofir-Rosenfeld et al., 2008). This leads to 
suppression of p53 translation. When directly interacting with p53 mRNA via its RING domain, 
MDM2 exhibits impaired E3 ligase function and promotes p53 mRNA translation (Candeias et al., 
2008). In response to DNA damage, the Ser395 phosphorylated MDM2 by ATM not only inhibits 
MDM2 oligomerization, nuclear export and degradation of p53 (Maya et al., 2001), but also is 
required for the p53 mRNA-MDM2 interaction and subsequent p53 activation (Gajjar et al., 
2012).  
1.1.5 p53-independent functions of MDM2 in cancer 
While the main identity of MDM2 is as a negative regulator of p53 tumor suppressor 
(Chen et al., 1995; Freedman et al., 1999; Haupt et al., 1997; Honda et al., 1997; Marechal et al., 
1994; Roth et al., 1998), it is appreciated that MDM2 also elicits oncogenic activities through 
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p53-independent pathways. Using mouse models, Jones et al. demonstrated that exogenous 
expression of MDM2 in transgenic mice increases spontaneous tumor formation, and the 
spectrum of tumors are different in p53 wild-type versus p53 null backgrounds (Jones et al., 1998). 
MDM2 over-expression in p53-deficient mice leads to an increase in the incidence of sarcomas 
(Jones et al., 1998). Moreover the expression of MDM2 splice variants that do not retain the p53-
binding domain increases cellular transformation in the absence of wild-type p53 (reviewed in 
(Okoro et al., 2012)), further supporting the p53-independent roles of MDM2.  
The most extensively studied p53-independent function of MDM2 in tumorigenesis is cell 
cycle regulation. Mechanistically, MDM2 degrades RB, the negative regulator of cell cycle 
progression, via both ubiquitin dependent and independent mechanisms, leading to hampered G1 
arrest (Sdek et al., 2005; Uchida et al., 2005); A direct interaction between MDM2 and RB 
inhibits the RB-E2F-DNA complex formation, thus liberating E2F from RB-mediated suppression 
(Sdek et al., 2004); MDM2 reportedly binds to E2F1/DP1 and increases their activities (Martin et 
al., 1995). Finally MDM2 facilitates p21 degradation by bridging the binding of p21 to 
proteasomal C8 subunit, leading to growth promotion in prostate cancer cells (Zhang et al., 2004).  
MDM2 is also implicated in suppressing apoptosis and genomic stability independently of 
p53. The ERK mediated phosphorylation of Forkhead O3a transcription factor (FOXO3a) 
promotes the FOXO3a-MDM2 interactions and enhances FOXO3a degradation via an MDM2-
dependent ubiquitin-proteasome pathway. This results in a strong inhibition of apoptosis and an 
enhanced tumorigenesis (Yang et al., 2008). In response to irradiation, MDM2 binds to the 
internal ribosome entry site (IRES) in the 5’-UTR of mRNA of X-linked inhibitor of apoptosis 
protein (xiap). This leads to an enhanced translation of xiap mRNA and elevated anti-apoptotic 
activity to cancer cells (Gu et al., 2009). MX69, the dual inhibitor of MDM2 and XIAP has 
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recently had some success in a preclinical animal model of human Leukemia (Gu et al., 2016). In 
response to DNA double-strand break, MDM2 interacts with Nbs1, one of the components of the 
MRN complex, at sites of DNA damage. This leads to an attenuated repair and chromosome 
abnormalities in cancer cells (Alt et al., 2005). 
Lastly MDM2 has been implicated in promoting p53-independent cancer metastasis. In 
SKOV3 ovarian cancer cells, which contain a transcriptionally inactive p53 gene, MDM2 drives 
epithelial mesenchymal transition (EMT) and cell motility through promoting the activation of 
TGF-β-Smad pathway. This leads to increased snail/slug transcription and loss of E-Cadherin 
expression (Chen et al., 2017). Additionally MDM2 binds and stabilizes slug mRNA. The 
resulting increased SLUG protein in the absence of p53 leads to an increase in lung cancer cell 
invasiveness (Jung et al., 2013). The involvement of MDM2 in breast cancer metastasis will be 
discussed further in Chapter 1.3.3. 
1.2 MDMX  
1.2.1 Discovery and transcriptional regulation of MDMX 
Nine years after the discovery of MDM2, MDMX (MDM4) was identified as a p53 
binding protein in a mouse cDNA library screen and was named based on its highly conserved 
homology with MDM2 (Shvarts et al., 1996). The human mdmx gene is located on chromosome 1 
(cytogenetic band: 1q32) and spans roughly 37 kb (Parant et al., 2001b). Both human and mouse 
mdmx transcripts contain 11 exons. The mdmx gene is ubiquitously and constitutively expressed 
during embryonic development as well as adulthood (Jackson and Berberich, 1999; Parant et al., 
2001b). Similar to mdm2, p53 can induce mdmx transcription under stress conditions (Phillips et 
al., 2010; Wei et al., 2006). Mitogenic signaling such as K-Ras and insulin-like growth factor-1 
(IGF-1) have also been reported to activate the transcription of mdmx in a MAPK/ERK dependent 
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fashion (Gilkes et al., 2008). Finally, c-Ets-1 and Elk-1 appear to be critical to the basal activity of 
mdmx promoter in a panel of tumor cell lines (Gilkes et al., 2008).  
1.2.2 Alternative splicing of mdmx 
To date, six mdmx splice variants have been documented in tumors as well as cancer cell 
lines (Mancini et al., 2009). The mdmx gene produces mdmx-s splice variant that skips exon 6 
which leads to a frame-shift and a premature stop codon. The resulting protein retains p53-
binding domain but contains 26 unique residues due to frame-shift (Rallapalli et al., 1999). It has 
been reported that MDMX-S isoform is more effective in inhibiting p53 transactivation compared 
to MDMX-FL (Rallapalli et al., 1999; Rallapalli et al., 2003). Early studies have shown that 
overexpression of mdmx-s correlates with poor prognosis in many types of cancers (Bartel et al., 
2005; Dewaele et al., 2016; Lenos et al., 2012; Liu et al., 2012). Therefore it was proposed that 
the MDMX-S isoform can be used as a biomarker and therapeutic target. However the exact role 
and significance of MDMX-S has been a subject of debate. A transgenic mouse model with 
targeted mdmx exon 6 deletion has revealed that forced mdmx-s expression increases p53 activity 
in hypomorphic p53ΔP/ΔP mice. And this effect of MDMX-S is elicited by the coupled reduction of 
MDMX-FL rather than the increase of MDMX-S at the protein level (Bardot et al., 2015). A 
recent report addressed whether mdmx-s expression directly contributes to oncogenesis. Despite 
that overexpression of mdmx-s was observed in B-CLL patient samples, B cell lineage specific 
mdmx-s induction in mice does not accelerate tumor development or contribute to tumor 
aggressiveness (Pant et al., 2017). Based on the current evidence, it is unclear whether MDMX-S 
directly participates in tumorigenesis and perhaps the discrepancy between pre-clinical findings 
and clinical observations can be resolved by improving the animal models that better recapitulate 
human diseases. In addition to mdmx-s, other splice variants such as mdmx-g, mdmx-a, and mdmx-
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b have been implicated exhibiting oncogenic properties potentially through the stabilization of 
MDM2 (Giglio et al., 2005; Mancini et al., 2009). It still remains to be determined whether these 
splice variants can translate into endogenous proteins and if so, what would be the mechanisms 
for them in cancer development.  
1.2.3 Structural and functional comparison between MDMX and MDM2 
 
 
Figure 2. Protein domain comparison between MDMX and MDM2.  
Diagram showing human MDM2 (top) and MDMX (bottom) proteins. The two proteins share 
high homology for p53-binding domain and RING domain. MDMX contains a conserved WW 
motif but lacks NLS and NES in the central region. Adopted from (Karni-Schmidt et al., 2016).  
 
The full length human MDMX is composed of 490 amino acids, which are categorized 
into p53-binding, acidic, zinc and RING domains (Figure 2) (Shvarts et al., 1997; Shvarts et al., 
1996). Most domains between MDMX and MDM2 are conserved with the exception of the acidic 
region (Marine et al., 2007). The amino acids for critical interaction with p53 through its N-
terminus by MDMX and MDM2 are identical (Bottger et al., 1999). Yet structural analysis on the 
N-terminal domain of MDMX reveals that the p53-binding pocket of MDMX is smaller and 
shaped differently (closed conformation) than that of MDM2 when binding to the transactivation 
domain of p53 (Popowicz et al., 2008). In addition to p53, MDMX has been reported to interact 
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with mTOR through its N-terminal p53 binding domain (Mancini et al., 2017). Unlike MDM2, 
MDMX protein lacks NLS and NES and therefore is proposed to localize primarily to the 
cytoplasm (Migliorini et al., 2002). It requires interaction with other protein partners, particularly 
MDM2, to translocate into the nucleus in response to cellular stress (Migliorini et al., 2002). Of 
note, nuclear localization of MDMX has been detected in melanoma and paediatric Burkitt 
lymphoma, implying deregulation of MDMX protein localization in cancer(Gembarska et al., 
2012; Leventaki et al., 2012). The acidic domain of MDMX can interact with the N-terminal and 
C-terminal domains of MDMX itself, as well as with the p53 DNA-binding domain to interfere 
the DNA binding functions of p53 (Wei et al., 2016). Prior to the central acidic domain, there 
exists a sequence around Trp200/Trp201 amino acid residues termed WW motif (Figure 2). 
Interestingly this WW motif has been shown to bind to MDMX N-terminal p53 binding pocket 
and reduces its p53 binding affinity, thus inhibiting the MDMX-p53 binding (Bista et al., 2013; 
Chen et al., 2015). The RING domain of MDMX does not have E3 ligase activity but is sufficient 
for an interaction with MDM2. Heterodimerization of MDMX and MDM2 by the RING domain 
stabilizes MDM2 and enhances its E3 ligase activity, leading to efficient inhibition of p53 (Kawai 
et al., 2007; Sharp et al., 1999; Tanimura et al., 1999). Notably MDMX is also a target for 
MDM2-mediated ubiquitination and degradation by the proteasomes (Pan and Chen, 2003).  
1.2.4 The MDMX-p53 regulation  
A global mapping of p53 binding sites reveals mdmx as one of the p53 target genes with 
p53 binding site in the first intron of mdmx (Wei et al., 2006). When induced by p53 activation in 
response of cellular stress, mdmx mRNA can be generated via a P2 promotor that makes mRNA 
efficiently translated into full length MDMX protein (MDMX-FL) (Phillips et al., 2010). In a 
recent report, Fahraeus’s research team discovered that overexpression of p53 binds to the 5’ 
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untranslated region (UTR) of mdmx mRNA and suppresses its translation (Tournillon et al., 2017), 
adding more complexity to the transcriptional and posttranscriptional control of MDMX by p53.  
MDMX and MDM2 are intimately linked with p53 regulation. In response to DNA 
damage, MDM2 preferentially targets MDMX for proteasomal degradation (Kawai et al., 2003), 
and phosphorylation of MDMX at Ser367 by 14-3-3 protein facilitates the down-regulation of 
MDMX, leading to p53 reactivation (Okamoto et al., 2005). While biochemical analyses have 
demonstrated the co-dependency between MDM2 and MDMX in regulating each other, as well as 
in controlling p53, direct in vivo evidence underscores the importance of MDM2-MDMX 
complex formation during embryonic development. MDMX RING domain mutant (C462A) and 
RING domain deletion that are deficient for MDM2 heterodimerization but proficient for p53-
binding caused embryonic lethality. These phenotypes can be rescued by the deletion of p53, 
highlighting the physiological requirement of MDM2-MDMX heterocomplex formation in 
controlling p53 during embryogenesis (Huang et al., 2011; Pant et al., 2011).  
Although a large body of evidence demonstrating MDMX inhibits p53 by cooperating 
with MDM2, MDMX alone can regulate p53. Just as important as MDM2, MDMX is critical in 
keeping p53 in check during embryonic development. While mdm2 knockout mice display 
embryonic lethality due to massive induction of apoptosis (de Rozieres et al., 2000), mdmx 
knockout mice result in p53-dependent embryonic lethality due to loss of cell proliferation at 7.5-
8.5 dpc (Parant et al., 2001a). This indicates that MDM2 suppresses p53 induced apoptosis and 
MDMX mainly blocks the p53-induced cell cycle arrest. Despite the remarkable homology 
between MDM2 and MDMX, MDM2 does not compensate for the loss of MDMX in a tissue 
specific manner. For instance, mdmx knockout in mouse cardiomyocytes and erythroid progenitor 
cells give rise to distinct phenotypes compared to the deletion of mdm2 in these lineages (Maetens 
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et al., 2007; Xiong et al., 2007). All these phenotypes can be rescued by the additional deletion of 
p53, suggesting non-overlapping functions of MDM2 and MDMX in suppressing p53. MDMX 
lacks intrinsic E3 ligase activity, and is associated with p53 transactivation inhibition. MDMX 
can directly bind to the transactivation domain of p53 (Shvarts et al., 1996), and is able to form 
MDMX-p53-DNA complex in the absence of p53 acetylation (Tang et al., 2008). The 
overexpression of MDMX compromises Nutlin-3 induced reactivation of p53 (Hu et al., 2006a), 
further supporting the notion that MDMX mainly represses p53 activity. 
1.2.5 Context specific p53-independent functions of MDMX 
Compared to MDM2, data for p53-independent functions of MDMX are less studied. 
MDMX can promote cell proliferation by suppressing several cell cycle checkpoint inhibitors. 
Firstly, MDMX interacts with p21 and induces its proteasomal turnover in a p53-independent 
manner (Jin et al., 2008). In a subset of uveal melanoma cell lines, MDMX elicits p53-
independent growth promoting effect in part by suppressing p27 protein expression (de Lange 
et al., 2012). Finally MDMX promotes RB degradation thus resulting in cell cycle progression 
via E2F1 activation (Zhang et al., 2015).  
Similar to MDM2, MDMX is able to interact with Nbs1 in a MDM2 and p53 
independent manner to prevent early DNA double-strand break repair, thus leading to genomic 
instability and enhanced cellular transformation (Carrillo et al., 2015). Paradoxically p53 and 
MDMX double null mice with MDM2 overexpression show accelerated tumor formation 
compared to MDMX+/+ p53-/- animals, indicating a tumor-suppressing role of MDMX in vivo 
(Steinman et al., 2005). In a subsequent study, the loss of MDMX increases the growth potential 
of p53-null MEFs over time caused by an enhanced multipolar mitosis (Matijasevic et al., 2008), 
providing a mechanistic explanation for the tumor suppressing function of MDMX. In aggregate, 
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the roles of MDMX in tumor development appear to be highly context-dependent and it remains 
to be elucidated whether these unexpected roles of MDMX are of relevance to human cancers. 
1.3 The roles of MDM2 and MDMX in breast cancer 
1.3.1 Breast cancer subtypes, development and metastasis manifestation 
1.3.1.1 Intrinsic subtypes of breast carcinoma  
Breast cancer is one of the most frequent cancers and remains the second leading cause of 
cancer-related deaths among women (DeSantis et al., 2017). Based on the molecular 
characteristics and histological profiles, breast cancer is classified into four main subtypes: 
luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)-enriched and Triple-
negative breast cancer (Hu et al., 2006b; Perou et al., 2000).  
Luminal A and B subtypes are largely estrogen receptor α (ERα) and/or progesterone 
receptor (PR) positive and HER2 negative. About 66% of breast tumors contain one of the two 
receptors (Clark et al. 1984). These subtypes activate the growth and proliferation in respond to 
estrogen signaling and can be targeted by anti-estrogen endocrine therapy (Jordan and Brodie 
2007). HER2-enriched subtype is hormone-receptor negative and HER2 positive, which often is a 
result of her2 amplification. The triple-negative breast cancers (TNBCs) subtype is frequently 
negative for ER, PR and HER2, and is a heterogenous group that includes basal-like and claudin-
low subsets (Prat et al., 2010). The basal-like subset of TNBC expresses myoepithelial markers 
such as cytokeratin 5/6. The claudin-low subset are characterized by low levels of tight junction 
(TJs) proteins including claudin 3, 4, 7 and adhesion junction (AJs) proteins such as E-Cadherin 
with tumor initiating cell associated features (Creighton et al., 2009; Hennessy et al., 2009; 
Herschkowitz et al., 2007; Sorlie et al., 2001). This subtype of breast cancer has the highest p53 
mutation frequency (Cancer Genome Atlas, 2012).  
15  
1.3.1.2 Stages and molecular events in breast cancer progression  
Despite the remarkable advancement in strategies targeting primary breast tumor, the 
majority of breast cancer associated fatalities are due to metastasis, and treatments are often 
restricted and ineffective (Chaffer and Weinberg, 2011; DeSantis et al., 2014; Siegel et al., 2013). 
Solid tumor metastasis is a result of disseminated tumor cells initiating new tumors at distant 
organs. A traditional invasion-metastasis cascade involves several steps: increased cell motility, 
enhanced local invasion, shedding of cancer cells into circulatory systems, survival in the 
circulation, arrested and exit in the secondary organs, dormant and reactivation of growth (Figure 
3) (reviewed in (Obenauf and Massague, 2015; Valastyan and Weinberg, 2011)).  
It is believed that the prerequisite for carcinoma cells to initiate the metastasis is to acquire 
cell migratory and invasive features. The loss of the expression of cell adhesion molecule E-
Cadherin directly causes the epithelial adenoma transition to carcinoma in transgenic mice (Perl et 
al., 1998). The repression of E-Cadherin is mediated by a developmental regulatory program 
termed epithelial mesenchymal transition (EMT) which has been linked with cancer metastasis 
(reviewed in (Thiery et al., 2009)). Two members of SNAIL transcription factor superfamily, 
SNAIL and SLUG, as well as zinc finger E-box binding homeobox 1 (ZEB1) and TWIST, are 
master transcription repressors for E-Cadherin in inducing EMT to promote cell invasion and 
migration, prevent apoptosis, and promote breast cancer stem cell activities (Bolos et al., 2003; 
Guo et al., 2012; Hajra et al., 2002; Wu et al., 2005).  
Although it is thought that cells obtaining access to the circulatory system, also called 
intravasation, after EMT initiation and local-stromal invasion, other mechanisms can take place to 
facilitate cancer cell dissemination. Tumor associated angiogenesis and lymphangiogenesis has 
been implicated in facilitating the entrance of cancer cells into circulation (reviewed in (Chiang et 
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al., 2016)). The best-characterized angiogenic factor is vascular endothelial growth factor (VEGF). 
A PyMT spontaneous breast cancer mouse model study has revealed that intravasation events 
directly correlate with the degree of vascular permeability, and both phenotypes can be mitigated 
by VEGFA inhibition (Harney et al., 2015). This provides a direct connection between 
angiogenesis and intravasation mediated by VEGFA. 
 
 
Figure 3. Main steps of metastasis manifestation in the invasion-metastasis model.  
During metastatic progression, tumor cells acquire invasive properties and enter the circulatory 
system. Upon circulation throughout the body, very few cells are arrested at secondary organ. 
Cells must be able to adopt the host environment and reactivate proliferation to form clinically 
detectable metastases. Adopted from (Valastyan and Weinberg, 2011). 
Tumor cells in circulation represents an intermediate stage during metastatic cascade. 
While transient and rare, these circulating tumor cells (CTCs) present a unique platform for 
evaluating the metastatic potential of cancer cells. A direct correlation between CTC counts and 
survival in patients with lung, colorectal, prostate and breast cancer have been demonstrated 
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(Cohen et al., 2009; Cristofanilli et al., 2004; de Bono et al., 2008; Krebs et al., 2011). Although 
the majority of the travelling CTCs will be rapidly cleared, a small fraction of CTCs can survive 
this hostile journey and eventually colonize in distant host organ. 
Breast cancer frequently metastasizes to the lung, bone, brain, liver and distant lymph 
nodes, with bone being the most common site of metastasis (Weilbaecher et al., 2011). Less 
incidence of skin and ovaries metastases is reported (Budczies et al., 2015). Several studies found 
that different subtypes of breast cancer favor distinct metastatic sites. Analysis on patients with 
different breast cancer subtypes revealed that bone is the most common secondary site across all 
the subtypes except basal-like breast cancer. Unlike hormonal receptor positive/HER2 negative 
subtype, TNBCs and HER2-enriched subtypes have a significantly higher rate of visceral organ 
metastases such as brain, liver and lung (Kennecke et al., 2010; Smid et al., 2008; Soni et al., 
2015; Wu et al., 2017). Works done by the Massagué lab identified gene expression profiles in 
mediating organ-specific breast cancer metastasis. High expression of several key genes 
associated with bone metastasis (ctgf, il-11, cxcr4, mmp1, adamts1 and fgf5) and lung metastasis 
(ptgs2, sparc, vcam1, mmp2, angptl4) were readily identified in MDA-MB-231 cells (Kang et al., 
2003; Minn et al., 2005). Since then numerous transcriptomic associated gene signatures of breast 
tumor cells have been extensively investigated and documented (Chen et al., 2018; Kimbung et al., 
2015; Lu and Kang, 2007).  
1.3.2 MDM2 and MDMX are overexpressed in breast cancer 
The overexpression of MDM2 takes place mainly by three mechanisms: gene 
amplification (Meddeb et al., 1996; Oliner et al., 1992), increased transcription (Bueso-Ramos et 
al., 1993; Watanabe et al., 1994) and enhanced translation (Landers et al., 1997; Landers et al., 
1994; Zhang and Wang, 2000). Genome-wide data analysis has identified mdm2 overexpression 
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across all subtypes of breast cancer (Cancer Genome Atlas, 2012). Importantly a single nucleotide 
polymorphism (T to G) at position 309 (SNP309) leads to MDM2 overexpression. This correlates 
with early age of tumor onset in women (Bond et al., 2006) and increases breast cancer risk in 
Scottish (Paulin et al., 2008), Asian and African population (Economopoulos and Sergentanis, 
2010; Sun et al., 2009; Zhao et al., 2012). Elevated MDM2 expression in breast cancer has been 
clinically observed and identified as an independent prognostic biomarker (Bueso-Ramos et al., 
1996; Park et al., 2014; Turbin et al., 2006; Yu et al., 2014). 
Mdmx gain is more frequent in breast cancer compared to mdm2 (Figure 4). An important 
mechanism for mdmx overexpression is genomic amplification. Its chromosomal location 1q32 is 
one of the most frequently amplified regions in human malignancies (Kovacs, 1978; Oshimura et 
al., 1976; Rowley, 1977). Yu and colleagues have identified that low-level mdmx amplification 
occurs at 56% breast cancer patients using FISH (Yu et al., 2014), providing supportive evidence 
on the mechanism of mdmx overexpression. Recently MDMX has been identified as a direct 
transcriptional target of ER, and elevated MDMX correlates with ER positive disease regardless 
of p53 mutation status (Swetzig et al., 2016). This provides another explanation for how mdmx is 





Figure 4. Genomic profiles of breast cancer patients in METABRIC database. 
Top diagram shows ER, MDM2, MDMX and p53 alterations in corresponding subtypes. Bottom 
diagram depicts frequency of amplification, mRNA deregulation and mutation events. Adopted 
from (Miranda et al., 2017)   
 
The overexpression of mdm2 and mdmx in claudin-low and basal subtypes is less frequent, 
possibly due to high mutation rate for p53. However there is a subset of breast cancers that retain 
overexpression of mdm2 or mdmx (Figure 4 and reviewed in (Haupt et al., 2017)). This suggests 
additional oncogenic functions of MDM2 and MDMX in TNBC. In mtp53 expressing breast 
cancer cell lines, MDMX expression appears to be elevated by post-transcriptional regulations 
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rather than genomic amplification or increased transcript levels (Miranda et al., 2017). This 
implies multiple regulatory pathways involved in increasing the expression of MDMX. 
1.3.3 MDM2 in breast cancer development and metastasis 
The importance of MDM2 in breast cancer development was first demonstrated in a 
transgenic mouse model where overexpression of mdm2 in mammary gland caused tumor 
formation and altered breast morphogenesis. This was correlated with an increased polyploidy of 
epithelial cells due to multiple rounds of DNA synthesis uncoupled from cell division (Lundgren 
et al., 1997). It is therefore proposed that MDM2 plays a major role in cell cycle regulation in 
breast cancers. We and others have demonstrated that MDM2 promotes breast cancer cell 
proliferation in both p53 dependent and independent manners (Brekman et al., 2011; Geng et al., 
2013; Kundu et al., 2017; Li et al., 2015), highlighting the importance of MDM2 in provoking 
breast tumorigenesis.  
The characterization of MDM2 in breast cancer metastasis has largely focused on EMT 
associated cell motility and invasiveness. MDM2 targets E-Cadherin for ubiquitination and 
degradation (Yang et al., 2006), and upregulates matrix metalloprotease 9 (MMP9) in cultured 
cells (Chen et al., 2013). Co-expression of MDM2 and MMP9 are detected in invasive ductal 
carcinoma (IDC) tissue (Chen et al., 2013). Furthermore MDM2 reportedly induces EMT by 
elevating SNAIL protein levels (Lu et al., 2016). This data suggests MDM2 possesses important 
functions in breast cancer invasion and metastasis by inhibiting E-Cadherin and activating 
molecules involved in the degradation of extracellular matrix. The in vivo role of MDM2 in 
metastasis has recently been investigated where MDM2 mediates breast cancer metastases to lung 
in TNBC xenograft models (Hauck et al., 2017).  
21  
Although an increasing body of evidence suggests MDM2 promotes breast cancer 
metastasis, such activity can be highly context specific. Several reports have implicated MDM2 as 
a metastasis suppressor. A recent report showed that microRNA mir-5003-3p promotes EMT by 
directly targeting MDM2 3’-UTR. This results in SNAIL stabilization and an enhanced MCF-7 
cell invasion that can be abrogated by MDM2 knockdown (Kwak et al., 2016). In the presence of 
wtp53, MDM2 induces the degradation of SLUG protein by forming a MDM2-SLUG-p53 ternary 
complex, leading to reduced breast cancer cell invasiveness and motility (Wang et al., 2009). In 
aggregate, current evidence suggests differential functions of MDM2 in association with different 
p53 status. This and other context dependent functions warrant further illustration.   
1.3.4 MDMX in breast cancer development 
Studies on the role of MDMX in breast cancer development is mostly ascribed to MDMX-
mediated cell proliferation. In breast cancer cells harboring wtp53, down-regulation of MDMX 
activates p21 expression, impedes cell proliferation and orthotopic tumor growth (Haupt et al., 
2015). The p53 inhibitor pifithrin-α (PFTα) partially rescues the growth impediment induced by 
MDM2 knockdown, indicating MDMX contributes to breast cancer cell proliferation in a p53-
dependent manner (Haupt et al., 2015). Similar observations were made in metastatic breast 
cancers bearing GOF mtp53, where MDMX knockdown dampens cell proliferation and 
attenuates tumor growth by elevating p27 expression in some breast cancer cell lines (Miranda 
et al., 2017). To date, no effort has been made to directly address the role of MDMX in breast 
cancer metastasis. Because of the abundance of MDMX in human breast tumors, and the 
structural homology between MDM2 and MDMX, it is therefore important to investigate the 
biological outcomes of MDMX in breast cancer progression. 
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In this thesis work, we aim to compare the p53-independent biological outcomes of 
MDM2 and MDMX in ER+ and TNBC breast cancer cell proliferation and metastasis. To do this 
we used T47D (ER+) and MDA-MB-231 (TNBC) breast cancer cells as representative for each 
subtype. 
Table 1. Cell lines examined in this study. 
 












T47D Luminal A ER+, PR+, 
HER2- 

















CHAPTER 2:  
MATERIAL AND METHOD 
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2.1 Cell culture 
Human breast cancer cell lines T47D and MDA-MB-231 were purchased from American 
Type Culture Collection (ATCC). Cells were maintained in DMEM (Invitrogen) media 
supplemented with 10% fetal bovine serum (FBS, Gemini), 50 U/ml penicillin and 50 µg 
streptomycin (Mediatech) at 5% CO2 37°C humidified incubator. T47D cells with inducible 
mdm2 knockdown were generated and described by Dr. Brekman and Dr. Kundu (Brekman et al., 
2011; Kundu et al., 2017).  
2.2 Bacterial culture and molecular cloning 
Bacterial growth - Echeseria coli were grown on LB (Luria-Bertani (1% Bacto-tryptone, 
0.5% Bacto-yeast extract, 1% NaCl) - Ampicillin (100 µg/ml))-Agar plates overnight at 37ºC. 
Colonies were grown in LB-Broth with Ampicillin (50 µg/ml) overnight at 37ºC shaking at 300 
rpm.  
Cloning - Cloning of shRNA sequences into MLP.1224 and STGM PGK PURO (MLP 
and STGM) vectors were done by Jill Bargonetti, Angelika Brekman, Alla Polotskaia and 
Mandeep Kaur. 
2.3 Generation of constitutive shmdm2 and shmdmx expressing cell lines 
2.3.1 shRNA sequences  




Clone ID Position shRNA sequence 
mdm2 151656 1793…1811  CTGTCTATAAGAGAATTAT 
mdm2 151657 1836...1854 GAATTTAGACAACCTGAAA 
mdmx 13023 246…264  GGTGAAATGTTCACTGTTA 
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We tested shmdm2 cell lines created using two different shRNA sequences and obtained 
similar results (data not shown). In this thesis we will present data using cell line containing 
mdm2 151656 sequence. 
2.3.2 Transient transfection of phoenix packaging cells 
Phoenix packaging cells were plated at 5x106 cells per 10 cm plate and incubate overnight. 
Media was then changed to 9 ml of complete DMEM media supplemented with 25 µM 
chloroquine. 20 µg MLP (with/without shRNA) and 5 µg of Helper plasmid DNA were mixed 
with 2 M CaCl2 in 0.01 M HEPES pH 5.5 and sterile water into 2X BBS (50 mM BES, 280 mM 
NaCl, 1.5 mM Na2HPO4 at pH 6.95) drop by drop with bubbling. Mixture was then added into the 
packaging cells and incubated overnight. Next day, changed media on packaging cells twice with 
at least 8 h intervals (7 ml per 10 cm plate) and incubate overnight. The following day collected 
media containing virus every 5 hrs and replenished with fresh media. Viral containing media were 
filtered through 0.45 µm syringe filter to either use immediately or freeze at -80ºC.  
2.3.3 Retroviral-mediated gene transfer 
Cells were seeded 30% confluency one day before infection into 10 cm plate. On the day 
of infection, viral containing media were diluted (1:2 ratio) with fresh media and combined with 
10 µg/ml polybrene before adding to the targeting cells (7 ml per 10 cm plate). The plate was then 
incubated for 5 hrs at 37°C. Replace with fresh infection cocktail and repeat the incubation for 
another 5 hrs. Remove the infection cocktail and replace with fresh media. Cells were grown 
overnight before being split into 5 µg/ml of Puromycin containing media for selection over 7 days. 
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2.4 RNA isolation, quantitative real-time RT-PCR and microarray analysis 
RNA was extracted using QIA shredder columns and RNeasy Mini Kit (Qiagen) 
following manufacturer’s protocol. cDNA synthesis was carried out using the High Capacity 
cDNA Archive Kit reagents (Applied Biosystems). RT master mix and RNA were mixed and 
incubated at 25ºC for 10 min and then at 37ºC for 2 hrs. Amplification of gene transcripts by 
quantitative PCR with primer probes for mdm2 (3-4) (Hs01069930_m1), mdmx (Hs00910358_s1), 
cxcr4 (Hs00607978_s1), ptgs2 (Hs00153133_m1) and gapdh (Ha02758991_g1) from Applied 
Biosystems. Primers were combined with 150 ng cDNA and Taqman Universal Master Mix 
(Applied Biosystems) and reaction was carried out using standard program in QuantStudio 7 
sequence detection system (Applied Biosystems). 25 ng of cDNA from tumor samples were used 
in TaqMan™ Array Human Tumor Metastasis (Applied Biosystems Cat # 4414098), Human 
NFKB pathway (Applied Biosystems Cat # 4414095) and Human Angiogenesis Array (Applied 
Biosystems Cat # 4378725) following manufacturers’ protocol. Gene expression analysis was 
performed with ExpressionSuite Software by Thermo Fisher Scientific.  
2.5 In vitro transcription/translation 
100 ng of pT7CFE1-CHis vector containing either no DNA, mdm2-fl or mdm2-c cDNA 
was mixed with HeLa lysate, accessory proteins, reaction mix, nuclease-free water provided by 1-
Step Human Coupled IVT Kit (Thermo Scientific Cat # 88881). Reaction was incubated for 90 
minutes at 30ºC and was stopped by placing on ice. The resulting protein product was resolved on 
a 10% polyacrylamide gel.  
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2.6 Whole cell extraction 
Cells were harvested at 1100 rpm for 5 min at 4°C, washed three times with ice-cold PBS 
and resuspended in RIPA buffer (0.1% SDS, 1% IGEPAL NP-40, 0.5% Deoxycholate, 150 mM 
NaCl, 1 mM EDTA, 0.5 mM EGTA, 50 mM Tris-Cl pH 8.0, 1 mM PMSF, 8.5 µg/ml Aprotinin, 
and 2 µg/ml Leupeptin). The cell suspension was incubated on ice for 30 to 60 minutes to lyse the 
cells, vortexing occasionally. Additional sonication of lysate for 3 times for 30 seconds/ 30 
seconds rest on ice at 98% amplitude was done when deemed necessary. Samples centrifuged at 
13,000 rpm for 20 min at 40ºC. The supernatants were stored at -80ºC. 
2.7 Immunoblotting assay 
4X NuPAGE Lithium dodecyl Sulfate buffer (Life Technologies) and 20 mM DTT were 
added to protein extracts and samples were heated at 70ºC for 10 min. 100 mM of Iodoacetamide 
(Sigma) was then added to the samples when cooled down. SDS-PAGE was used to separate 
samples followed by electrotransfer onto nitrocellulose membrane. Membrane was blocked with 
5% non-fat milk (Biorad) in either 1X PBS-0.1% Tween-20 or 1X TBS-0.1% Tween-20 
following incubation of primary antibody overnight at 4ºC. The next day membrane was washed 
with either 1X PBS-0.1% Tween-20 or 1X TBS-0.1% Tween-20 and then incubated with 
secondary antibody for 1hr at room temperature. Signal was detected by chemiluminescence with 
Super Signal Kit (Pierce) and autoradiography with Hyblot CL films (Denville Scientific). 
2.8 Immunofluorescence 
Cells were grown in either 12 well glass bottom plates (MatTek) at 50% confluency 
overnight, then fixed with 4% paraformaldehyde, permeabilized with 0.5% Triton-X-100 in 
PBS/1% horse serum for 10 minutes, blocked and stained with primary antibodies summarized 
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below for 1 hour at room temperature. Alexa Fluor conjugated secondary antibody (Invitrogen) 
was then used and cells were mounted with Vectashield mounting medium containing DAPI 
(Fisher Scientific). Image was captured by Nikon A1 Confocal microscope at 600X magnification 
and analyzed by NIS-Elements AR Analysis software. 
2.9 Antibodies 
Antibodies used for Western Blot analysis: MDM2 - 1:1:1 mix of mouse monoclonal 4B2, 
2A9, 4B11 hybridoma supernatant, p53 - 1:1:1 mix of mouse monoclonal 240,421,1801 
hybridoma supernatant, MDMX (Proteintech), Actin HRP (Santa Cruz) and E-Cadherin (Cell 
Signaling). 
Antibodies used for immunofluorescence analysis: IF2 (Thermo Fisher Scientific 33-
7100), Santa Cruz (sc-954) and Rhodamine-Phalloidin (Cytoskeleton BK005). 
MDM2-C specific 7C7-B6 hybridoma supernatant were tested in Western Blot and 
immunofluorescence analyses and demonstrated in Chapter 6.2.3. 
2.10 Cell proliferation assay  
50,000 MDA-MB-231 cells/well were seeded in 6-well plate in triplicate and were 
allowed to grow for 2, 4, 5, and 6 days, respectively. At each time point, cells were trypsinized 
and the number of cells were determined by hemocytometer cell counting. Graph shows means 
and standard deviations of three independent experiments.  
2.11 MTT assay 
The mitochondrial activity was measured with etrazolium dye-based microtitration assay. 
Briefly, 20,000 cells/well were seeded in 12-well plate. After 5 days of doxycycline treatment, 5 
mg/ml of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution was 
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added to the cells at a volume equal to 10% of cell culture medium. Cells were then incubated at 
37ºC until color changed. MTT solubilization solution (90% anhydrous isopropanol, 10% Triton 
X-100, and 0.826% 12.1N HCl) was added to volume equal to original culture medium and 
crystals were dissolved by pipetting. The absorbance was measured at 550 nm and 620 nm 
(background) and was quantified by plate spectrophotometer. 
2.12 Wound healing assay 
800,000 cells/well were plated in 6 well plate one night before the experiment. Scratches 
were created using a 200 μl pipette tip. Cells were then rinsed 3 times with fresh medium. Wound 
closure was observed within the scrape line and photographed by phase-contrast microscopy. 
Wound area was measured and quantified by NIS element software. 25-30 fields per condition 
were recorded and 3 independent experiments were performed. 
2.13 Orthotopic tumor implantation and measurement 
For T47D study, MDM2 knockdown was induced with 4 μg/ml in cell culture condition 
for 10 days before implantation. 1x107 tumor cells were then injected into the mammary fat pad 
of female NOD-scid gamma (NSG) mice at 6 weeks of age. Animals are provided with drinking 
water containing 2 mg/ml Doxycycline (Sigma) dissolved in deionized water, 8 μg/ml 17β-
Estradiol (Sigma) dissolved in DMSO, 2% sucrose (Sigma) and replenished every other day. For 
MDA-MB-231 study, 1x107 cells with constitutive MDM2 or MDMX knockdown were injected 
into the right mammary fat pad of female NOD-scid gamma (NSG) mice at 6 weeks of age. No 
additional drug was administered. Tumor growth was measured using calipers and tumor volume 
was calculated as volume = π/6 (length x width x width). At ethical endpoint mice were sacrificed 
following institute guidelines.  
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2.14 Circulating tumor cell analysis 
Cardiac punctures were performed at endpoint of the experiment and blood samples were 
stored temporarily in 1.5 mL microcentrifuge tubes coated with sodium heparin (Sagent 
Pharmaceuticals) prior to CTC isolation procedure. Briefly, whole blood was subjected to 
centrifugation. After removal of plasma, the buffy coat layers were then collected and subjected to 
red blood cell (RBC) lysis to remove residual RBCs. Flow cytometry analysis was performed on 
FACScan device (BD Biosciences), and event counting was gated based on size and GFP 
intensity from cultured cells as positive control. The number of CTCs were obtained by dividing 
number of positive events with individual blood volume. Statistical significance was calculated by 
two sample Permutation test, two-sided hypothesis after multiplicity adjustment (Hochberg 
procedure). 
2.15 Tissue processing and histology 
Tissue processing and Animal tissues were harvested, fixed in 10% buffered formalin and 
paraffin-embedded (FFPE). Sections of primary tumors and lungs were cut at 5 microns and 
stained with hematoxylin and eosin (H&E) by the Laboratory of Comparative Pathology. The 
slides were analyzed by a board-certified veterinary pathologist at Memorial Sloan Kettering 
Cancer Center (MSKCC).  
2.16 Lung metastases quantification 
Lung metastases burden was scored by counting colonies that have more than 10 cells on 
the long axis. 15 random fields were scored per animal lung. The total number of lung foci the 
sum of colonies from all 15 fields. 
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2.17 Statistics 
CTC data obtained from MDA-MB-231 animal study were analyzed in statistical software 
R (version 3.4.2). Datasets were tested for assumptions of normality using the Shapiro-Wilk test 
(Shapiro and Wilk, 1965). If the normality was confirmed, a pairwise independent t-test was 
carried out. Otherwise, for non-normal data, we applied a permutation based two sample t-test 
instead, which are appropriate for small samples from non-normal distributions. Hochberg 
correction (Gou et al., 2014; Hochberg, 1988) was performed on the resulting p-values for all 
multiple comparisons to control for the familywise error rate (Tamhane and Gou, 2018). All other 
graphs and statistical analysis were generated by GraphPad Prism 7.01 software. For box and 








MDM2 FACILITATES ER+ T47D XENOGRAFT 




MDM2 overexpression occurs at a 14-30% rate in Luminal A&B/ER+ breast cancer 
subtypes (Cancer Genome Atlas, 2012). Patients with high levels of MDM2 in both nuclear and 
cytoplasmic compartments have a poor prognosis (Park et al., 2014). Early studies identified a 
significant correlation between ER positivity and overexpression of MDM2 in human breast 
tumors as well as immortalized human breast cancer cell lines (Baunoch et al., 1996; Gudas et al., 
1995; Hori et al., 2002; Marchetti et al., 1995; Sheikh et al., 1993). This evidence strongly 
suggests MDM2 functions to promote ER+ breast cancer development. 
In ER+ breast cancer cells, estrogen drives mdm2 transcription by recruiting ER to the P2 
promoter, leading to the induction of mdm2 transcription (Kinyamu and Archer, 2003). 
Additionally many breast cancer cell lines have endogenous MDM2 overexpression due to 
SNP309 in intron 1, which activates the P2 promoter induced transcription of mdm2. A thymine 
(T) to guanine (G) change increases the binding affinity to the SP1 transcriptional activator, 
which is hypothesized to cooperate with ER to elevate endogenous mdm2 transcription (Bond et 
al., 2006; Bond et al., 2004; Hu et al., 2007). We reported that in breast cancer cells harboring 
SNP309T/G and G/G alleles, upregulated MDM2 in response to estrogen stimulation confers p53-
independent proliferative advantages in MCF-7 and T47D breast cancer cells (Brekman et al., 
2011; Kundu et al., 2017). These studies were carried out in regular cell culture and three-
dimensional culture conditions. Whether the p53-independent growth-promoting function of 
MDM2 in mtp53 expressing T47D breast cancer cells has in vivo significance has not been 
directly addressed.  
In order to obtain a more accurate assessment for the role of MDM2 in ER+ T47D breast 
tumor development, we incorporated the orthotopic implantation method using female NOD scid 
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gamma (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) (NSG) immunodeficient inbred lab mice as the model 
system. By injecting cancer cells into their organ of origin, the orthotopic implantation method 
reconstitutes the structural and signaling cues that best mimic the in vivo environment. 
Additionally compared to nude mice, the engrafted tumor growth is more permissive in NSG 
mice (Puchalapalli et al., 2016). Based on our in vitro findings, we predicted that estrogen 
activated MDM2 would provoke primary tumor development in T47D transplants. 
It has been documented that ectopic expression of MDM2 ubiquitinates and degrades E-
Cadherin (Yang et al., 2006), and is associated with elevated EMT phenotype in MCF-7 cells (Lu 
et al., 2016). These studies have demonstrated the ability of MDM2 to increase cellular 
invasiveness in ER+ breast cancer cells. We were interested in answering the question of whether 
upregulated MDM2 under the estrogen exposure could enhance tumor invasiveness in vivo. Based 
on published knowledge, we hypothesized that estrogen induced MDM2 upregulation in ER+ 
T47D breast cancer cells would enhance tumor invasiveness by down-regulating E-Cadherin. 
3.2 Results 
3.2.1 MDM2 strongly promotes ER+ T47D tumor growth in vivo 
T47D cells exhibit elevated mdm2 due to SNP309 G/G, and contain a mutant form of p53 
(L194F) that has been characterized as a loss of function mutant (Polotskaia et al., 2015). Using 
the previously established isogenic cell lines with inducible MDM2 knockdown, we assessed the 
in vivo role of MDM2 in T47D tumor development. Cells with or without induced shRNA-
mediated MDM2 knockdown were implanted into the mammary fat pads of mice. These animals 
were supplied with Doxycycline (Dox) and estrogen containing water to allow for studying the 
function of estrogen activated MDM2 in tumor progression. Consistent with our previous findings 
(Brekman et al., 2011; Kundu et al., 2017), when MDM2 was knocked down prior to implantation, 
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no change was observed for mtp53 protein levels (Figure 5A). E-Cadherin levels also remained 
unchanged upon MDM2 knockdown (Figure 5A). Fourteen days post implantation, all animals 
developed measurable tumors except one mouse from the MDM2 knockdown group. Within one 
month, we observed a slower tumor growth in the T47D.shmdm2 group compared to the 
T47D.vector control group (Figure 5B). The difference in primary tumor growth between the two 
biological groups was more profound and significant over time. A 50% reduction in the final 
tumor volume was confirmed after animals were sacrificed (Figure 5C), and this is the first in vivo 
proof that MDM2 drives estrogen-mediated ER+ breast cancer cell proliferation independently of 
wtp53. 
  
Figure 5. MDM2 knockdown in ER+ T47D orthotopic transplant reduces tumor volume.  
T47D cells with inducible shmdm2 or control vector were treated with 4 μg/ml doxycycline (Dox) 
for 10 days to induce and maintain shRNA expression. (A) Western Blot showed the levels of 
MDM2, E-Cadherin, and mtp53 of Dox treated cells (lane 1 and 2) prior to mammary fat pat 
implantation. Actin was used as loading control. (B) Animal were provided with 2 mg/ml Dox 
and 8 μg/ml E2 in drinking water during tumor development. Primary tumor growth was 
measured over a period of 60 days. *** represents p<0.001 and the p-value was calculated using 
two-tailed unpaired t-test. (C) Tumor volume was determined at the time of necropsy.  
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3.2.2 MDM2 does not increase primary tumor invasiveness or reduce E-Cadherin levels 
The tumor masses, despite the difference in size, did not exhibit any morphologic 
difference as the architecture and cytomorphology were maintained in all tumors in each mouse. 
Every mass was located within the mammary fat pad, between the skin and the muscle planes. 
The local invasiveness in terms of growth pattern (expansile and infiltrative) was not different 
between the two groups (Figure 6A), and knockdown of MDM2 did not decrease the percentage 
of infiltrative tumors (Figure 6B).  
 
Figure 6. MDM2 knockdown does not decrease T47D orthotopic transplant invasiveness. 
(A) Representative H&E staining images of T47D.vector and T47D.shmdm2 under 40X or 200X 
magnification. T represents Tumor, nm represents normal mammary fat pad, M represents Muscle, 
Arrow head depicts tumor cells infiltrating into muscle layer. (B) Percentage distribution of 
expansile and infiltrative tumors in T47D.vector (n=10) and T47D.shmdm2 (n=9) group.  
 
To validate our results, we analyzed the knockdown efficiency of MDM2 in the tumors by 
qRT-PCR and Western Blot. Mdm2 RNA was reduced by 55% and its protein levels were also 
significantly reduced by 75% (Figure 7A-B and C for MDM2 quantification). the E-Cadherin and 
mtp53 protein expression in T47D.shmdm2 primary tumors did not change comparing to 
T47D.vector tumors (Figure 7B and C for mtp53 and E-Cadherin quantification). Our data 
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showed that MDM2 promotes tumor growth in T47D transplants but does not increase tumor 
invasive properties or E-Cadherin protein expressions.  
  
Figure 7. MDM2 knockdown does not increase E-Cadherin or mtp53 protein levels in vivo. 
(A) mdm2 mRNA expression in primary tumors was determined by quantitative real-time RT-
PCR. The p-value was determined by two-tailed unpaired t-test. (B) E-Cadherin, MDM2 and 
mtp53 protein levels from primary tumors were determined by Western Blot analysis. Actin is 
served as loading control. (C) ImageJ quantification for MDM2, E-Cadherin and mtp53 protein 
levels of three individuals from either vector control group or shmdm2 group. The p-value was 
calculated by two-tailed unpaired t-test. NS represents non-significant. 
 
3.3 Discussion  
In this chapter we investigated the role of estrogen activated MDM2 in ER+ T47D cells in 
an in vivo mouse model. Previously published data suggests that MDM2 acts as a central hub to 
promote estrogen-mediated cell proliferation (Brekman et al., 2011; Kundu et al., 2017). Here we 
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showed that the estrogen-activated MDM2 strongly increases primary tumor volume (Figure 5). 
This provides an in vivo demonstration on the p53-independent growth promoting function of 
MDM2. Similar to regular cell culture results, primary tumor expressing shmdm2 did not change 
mtp53 levels. This is not a surprise as mtp53 is reportedly protected from MDM2 mediated 
degradation by heat shock proteins HSP70/90 chaperon machinery (reviewed in (Vijayakumaran 
et al., 2015)). As a result, many mtp53 proteins display prolonged stability. It has been shown that 
high MDM2 and low E-Cadherin levels are detected in breast cancer patients (Lu et al., 2016; 
Yang et al., 2006), and are more likely to exhibit axillary lymph node metastasis (Yang et al., 
2006). Here we showed that endogenous MDM2 knockdown in T47D cells alone did not change 
E-Cadherin levels in vitro and in vivo, suggesting additional factors may be required for efficient 
degradation of E-Cadherin (Figure 5A and 7B-C). Furthermore, our animal experiment showed 
that the primary tumor morphology was indistinguishable between control and MDM2 
knockdown group (Figure 6), suggesting MDM2 does not increase local invasion of T47D cells. 
In conclusion, these results indicate that MDM2 elicits in vivo p53-independent tumor growth-
promoting function but does not increase tumor invasiveness or decrease E-Cadherin protein 
levels.  
One possible mechanism by which MDM2 facilitates in vivo tumor development is the 
activation of E2F1 and inhibition of RB. MDM2 has been shown to stimulate E2F1 
transcriptional activity (Martin et al., 1995), increase E2F1 stability (Zhang et al., 2005) and 
degrade RB (Sdek et al., 2005; Uchida et al., 2005). We have recently shown that endogenously 
overexpressed MDM2 stimulates RB hyperphosphorylation and increases E2F1 protein levels in 
the presence of estrogen (Kundu et al., 2017). Additionally, ER antagonist fulvestrant decreases 
cell proliferation and blocks phosphorylation of RB via down-regulation of MDM2 (Kundu et al., 
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2017). It remains to be determined if tumor-associated E2F1 and phosphorylation of RB can be 















CHAPTER 4:  
MDM2 AND MDMX PROVOKE MDA-MB-231 




In Chapter 3, we showed that estrogen activated MDM2 does not increase tumor 
invasiveness or E-Cadherin expression in T47D breast cancer cells but drives p53-independent 
proliferation and tumor growth in vivo. In clinically aggressive TNBCs, MDM2 overexpression is 
seen in 14% breast tumors (Cancer Genome Atlas, 2012), and there exists some evidence on 
MDM2 promoting cell migration and EMT phenotype (Chen et al., 2013; Hauck et al., 2017; Lu 
et al., 2016). In mutant p53 expressing breast cancer cells, MDMX knockdown has recently been 
shown to inhibit proliferation and attenuate tumor growth in NSG xenograft models (Miranda et 
al., 2017). However its role in breast cancer metastasis has never been investigated. Clinical 
studies have shown that MDMX overexpression positively correlates with lymph node metastasis 
in gastric adenocarcinoma patients (Bao et al., 2016). Additionally high expression of MDMX in 
patients with non-small cell lung cancer (NSCLC) correlates with poor tumor cell differentiation, 
advanced stage and lymph node metastasis (Zhao et al., 2017). High levels of MDMX has been 
detected in TNBC biopsy samples (Miranda et al., 2017), suggesting the selection for MDMX 
may be of clinical importance in breast cancer prognosis. 
To explore the role of MDM2 and MDMX in TNBC, we used breast adenocarcinoma 
MDA-MB-231 in this study. This ER, PR and HER2 negative (triple negative) cell line belongs to 
the claudin-low subset of breast cancer. Molecularly, MDA-MB-231 cells carry a stabilized 
mtp53 (R280K), an endogenously overexpressed MDM2 owing to SNP309 T/G heterozygosity, 
and an elevated expression of MDMX possibly due to post-transcriptional regulation (Miranda et 
al., 2017). These cells do not express detectable E-Cadherin due to promoter methylation 
(Lombaerts et al., 2006). Therefore this cell line serves an excellent tool for studying MDM2 and 
MDMX in breast cancer progression because of its high levels of MDM2 and MDMX 
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expressions, extremely aggressive, poorly differentiated nature and extensive documentation on 
the molecular pathways involved in metastasis. Based on the clinical observation, as well as 
current knowledge on the function of MDM2 and MDMX in TNBC, we hypothesized that 
MDM2 actively contributes to the metastasis of MDA-MB-231 cells, and MDMX promotes both 
proliferation and metastasis properties.  
4.2 Results 
4.2.1 Inducible MDM2 knockdown does not change MDA-MB-231 cell proliferation 
We previously reported that MDM2 does not promote proliferation in triple negative 
MDA-MB-231 cells (Kundu et al., 2017). In response to MDM2 depletion after 5 days growing in 
2D culture condition, no change is observed in mtp53 expression, and cell numbers and viability 
remain unaltered (Figure 8). This suggests a context dependent biological function of MDM2 in 











Figure 8. MDM2 knockdown in triple negative MDA-MB-231 cells does not change 
proliferation.  
Inducible clonal MDA-MB-231 cells with mdm2 shRNA or vector control were grown with or 
without 6μg/ml doxycycline (Dox) for 5 days to induce shRNA expression. (A) Number of cells 
was determined by cell counting using hemocytometer after 5 days in either presence or absence 
of shRNA induction. Percentages of cell proliferation were obtained by normalizing to vector 
control or shmdm2 without shRNA induction. Mean values of two biological replicates are shown. 
(B) Mitochondrial activity was determined by MTT assay after 5 days in either the presence or 
absence of shRNA induction. Percentages of mitochondrial activity were obtained by normalizing 
to vector control or shmdm2 without shRNA induction. Error bars represent standard deviation of 
three biological replicates. NS: non-significant by Student’s t-test. (C) A representative image of 
Western Blot analysis of MDM2 and Actin protein levels from 50μg whole cell protein extract is 
shown. Modified from (Kundu et al., 2017). 
 
4.2.2 MDM2 down-regulation inhibits MDA-MB-231 cell migration 
To determine whether inducible MDM2 knockdown in these cells impedes cell migration, 
we performed the wound healing assay. In agreement with published findings (Chen et al., 2013; 
Hauck et al., 2017), we saw a 40% reduction in the percentage of wound closure when MDM2 




Figure 9. MDM2 knockdown impedes in vitro cell migration.  
MDA-MB-231 cells with inducible shmdm2 or control vector were used. (A-B) MDM2 
knockdown was induced by Dox for 5 days prior to the experiment. 800,000 cells/well were 
plated with or without Dox containing media one night before the experiment. Wound closure 
was observed by phase-contrast microscopy and photographed at 0 and 12 hours. Wound area was 
measured by NIS element software and quantified from four independent experiments. (C) 
Representative Western Blot demonstrating the levels of MDM2. Actin was served as loading 
control. **p<0.01 Student t-test. 
 
4.2.3 MDMX or MDM2 constitutive knockdown does not impede MDA-MB-231 cell 
proliferation but decreases cell migration 
MDM2 has recently been shown to promote in vivo triple negative breast cancer 
metastasis (Hauck et al., 2017). In tumor derived MDA-MB-231 (named TMD231) and mtp53 
(R273H) expressing MDA-MB-468 cells, MDM2 knockdown decreases lung metastatic foci 
formation (Hauck et al., 2017). This provides the ground work for the relevance of MDM2 in 
metastasis in TNBC. We were interested in determining if MDM2 in the original MDA-MB-231 
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cells could provoke early stage metastasis. Moreover, we discovered that in Claudin-low breast 
cancer subtype, mdmx gain is detected at 10% frequency (Figure 10), suggesting high levels of 
MDMX may contribute to the development and progression of this subset of breast cancer. This 
led us to investigate the biological function of MDMX in the context of MDA-MB-231 cells, a 
well-established claudin-low breast cancer cell line. 
 
Figure 10. MDM2 and MDM4 (MDMX) are overexpressed in Claudin-low/TNBC subset of 
breast cancer.  
Zoomed-in picture of MDM2 and MDMX genetic alteration frequency from patients with 
Claudin-low breast cancer. Data were derived from breast cancer METABRIC (Cancer Genome 
Atlas, 2012; Pereira et al., 2016) Claudin-low subtype data set as of September 2018. Raw data 
was processed on cBioPortal (Gao et al., 2013). Each bar represents one patient tumor analyzed. 
218 sequenced patients were included in this dataset.   
 
To better understand and compare the functions of MDM2 and MDMX, we generated cell 
lines containing constitutive shRNA mediated knockdown of MDM2 or MDMX with GFP 
expressing marker. These cell lines were maintained as a heterogenous pool as opposed to single 




Figure 11. shRNA mediated constitutive down-regulation of mdm2 and mdmx in MDA-MB-
231 cells.  
(A) Relative mRNA expression of mdm2, mdmx, and tp53 normalized to gapdh was shown. Error 
bars represent standard deviation from 4 independent biological replicates. (B) Representative 
Western Blot image of MDM2, MDMX, mtp53 and Actin in 231.vector, 231.shmdm2, and 
231.shmdmx isogenic cell lines. 50 µg of whole cell extract was loaded in each lane. (C) ImageJ 
analysis on the relative protein levels of MDM2, MDMX, and mtp53 normalized to Actin. Error 
bars represent standard deviation of three biological replicates. **represents p<0.01, *** 
represents p<0.001. NS represents non-significant. The p-value was calculated using two-tailed 
unpaired t-test.  
 
Cells with stable knockdown of MDM2 or MDMX remained viable thus enabling us to 
use them for future experiments. We next characterized them by qPCR and Western Blot analyses. 
Both mdm2 and mdmx shRNA construct efficiently induced mRNA down-regulation (Figure 
11A). At the protein levels, both MDM2 and MDMX were significantly decreased (Figure 11B-
C). Notably MDM2 knockdown is associated with a more than 2-fold increase for MDMX protein 
levels, indicating MDM2 functions as an E3 ligase towards MDMX (Figure 11B MDM2 and 
MDMX Western Blot compare lane 1 and 3, and 11C for MDMX quantification). Similarly, in 
these isogenic cell lines both mRNA and protein levels of mtp53 did not change with either 
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MDM2 or MDMX knockdown (Figure 11A-B mtp53 Western Blot and 11C for mtp53 
quantification).  
We then asked whether stable knockdown of MDMX or MDM2 promotes the MDA-MB-
231 proliferation and migration properties. Consistent with inducible MDM2 knockdown results, 
cell proliferation was not changed by stable MDM2 knockdown. Moreover, we did not see any 
difference in cell proliferation upon down-regulation of MDMX (Figure 12A). Instead, we saw 
that MDM2 and MDMX knockdown reduced the in vitro cell migration by 30% and 50% 





Figure 12. MDMX and MDM2 provoke in vitro MDA-MB-231 cell migration without 
changing cell proliferation.  
(A) Number of cells was determined by hemocytometer cell counting. 50,000 cells were seeded in 
triplicates and cell counting was performed at day 2, 4, 5 and 6. Dots represent mean values and 
error bars represent standard deviations. Experiments were carried out three times. (B) Wound 
closure was observed by phase-contrast microscopy and photographed at 0 and 12 hours. One 
representative image from each group at 0 and 12 hours was shown. (C) The wound area was 
measured by NIS element software. The percentage of wound closure was quantified from four 





4.2.4 MDMX and MDM2 knockdown profoundly decrease CTCs and lung metastasis 
 
 
We first asked if MDM2 or MDMX provokes metastasis in orthotopic tumors by 
examining if genetic knockdown of MDM2 or MDMX reduced CTC counts, tumor local-stromal 
invasion and lung metastatic burden (see Figure 13 for experimental design). Western Blot 
analysis showed a significant continuous reduction of MDM2 or MDMX prior to animal 
implantation (Figure 14A). When control MDA-MB-231 mir30-Vector (presented as 231.Vector 
in this thesis) cells were implanted into mice they generated an average of 693 circulating tumor 
cells per milliliter of blood (Figure 14B). In keeping with the ability of increased MDM2 and 
MDMX to promote cell migration, stable MDM2 knockdown in MDA-MB-231 shmdm2 
(231.shmdm2) cells resulted in a 78% reduction of CTCs (155 cells/ml), and MDMX knockdown 
Figure 13. Methodology for 
investigating MDA-MB-231 tumor 
development and metastasis.  
MDA-MB-231.vector, shmdm2, and 
shmdmx cells were orthotopically 
implanted into mammary fat pad of 
female NSG mice. Tumor size were 
measured twice a week until the end 
of the experiment. At the time of 
necropsy, animal blood was drawn 
via intracardiac puncture, and cancer 
cells were immediately isolated and 
subject to FACS analysis. Primary 
tumor tissues were resected and 
documented for final volume and 
analyzed for pathology, RNA and 
protein expressions. Animals’ lungs 
were stained with hematoxylin & 




in stable MDA-MB-231 shmdmx (231.shmdmx) knockdown profoundly decreased CTCs to 29 




Figure 14. MDMX and MDM2 knockdown in MDA-MB-231 orthotopic transplants reduce 
CTCs.  
MDA-MB-231 cells with constitutive shmdm2, shmdmx or control vector were implanted into 
mammary fat pad of 6 weeks old female NSG mice. (A) Western Blot analysis of MDM2, 
MDMX, and mtp53 protein levels from 50 μg whole cell lysates from 231.Vector, 231.shmdm2 
and 231.shmdmx cells (lanes 1, 2 and 3) prior to mammary fat pad implantation. Actin is shown 
as loading control. (B) The box and whisker plot represent the numbers of CTCs per milliliter 
from vector control, shmdm2 and shmdmx engrafted animals. The number of CTCs were 
determined by flow cytometry. Total events were counted, and gates were set via the GFP signal 
intensity and cell size. The number of CTCs per milliliter was obtained by dividing number of 
positive events with blood volume from individual animal. The adjusted p-value was obtained 
with two-tailed for the two-sample t-test using a permutation test. (C) Representative FACS plots 
showing GFP positive events in different mouse groups. 
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As seen in Figure 14, we established that the number of CTCs is dependent on MDM2 and 
MDMX. This led us to investigate whether the reduction of CTCs could result in a decreased lung 
metastasis in the animal. Histopathology assessment of the lungs revealed that 231.Vector cells 
residing in lungs form multiple identifiable metastases under low magnification (Figure 15A 
Vector upper panel). Quantitatively an average of 16 foci was observed per lung (Figure 15B). In 
keeping with published results (Hauck et al., 2017), MDM2 knockdown yielded lower lung 
metastases. Importantly MDMX knockdown significantly decreased the detectable lung foci 





Figure 15. MDM2 and MDMX knockdown decrease lung metastases burden in MDA-MB-
231 implanted animals.  
(A) Representative H&E stained images of animal lungs from 231.Vector (n=6), 231.shmdm2 
(n=7), or 231.shmdmx (n=7) group at 40X magnification (upper panel, scale bar 200 μm) or 200X 
magnification (lower panel, scale bar 50 μm). Arrow points to metastatic foci. (B) Quantitation of 
lung foci formation. The p-value was obtained using two-tailed unpaired t-test. 
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4.2.5 MDMX and MDM2 do not promote primary tumor development 
We next asked whether reduced CTCs in MDMX or MDM2 knockdown group might be 
due to reduced size of the primary tumors. Published results with knockdown of MDM2 in TMD-
231 cells show an inconclusive influence on tumor volume with no difference in the documented 
final weight (Hauck et al., 2017). We found that comparing to vector control group, depletion of 
MDM2 resulted in a non-statistically significant reduction in the average primary tumor volume 
(Figure 16A-B pink squares), and MDMX knockdown only caused a statistically significant 
smaller tumor volume at the early stage of measurements (up to day 26) (Figure 16A green 
triangles). By day 36, although there was a trend of reduction, the decrease was not statistically 
significant.  
To validate these findings, we confirmed in vivo knockdown of MDMX and MDM2 with 
qRT-PCR and Western Blot analysis (Figure 16C-D). A significant depletion of MDM2 at the 
mRNA and protein level resulted in an increase in MDMX protein (Figure 16C-D lanes 4, 5, and 
6). The shRNA-mediated decrease in mdmx mRNA was close to significance but the protein 
reduction of MDMX was clear (Figure 16C). Importantly, animals with MDMX protein depletion 





Figure 16. MDMX and MDM2 knockdown in MDA-MB-231 orthotopic transplants do not 
significantly reduce primary tumor volume.  
(A) Primary tumor volumes of 231.Vector (n=6), 231.shmdm2 (n=7) and 231.shmdmx (n=7) 
engrafted animals were measured by caliper over 36 days. (B) Tumor volumes were determined at 
the time of necropsy. (C) mRNA levels of mdm2, and mdmx normalized to gapdh in primary 
tumors were determined by quantitative real-time RT-PCR. Error bars represent standard 
deviations. (D) Protein expressions of MDM2, MDMX and mtp53 from 231.Vector, 231.shmdm2 
and 231.shmdmx engrafted primary tumors were determined by Western Blot analysis. Three 
representative tumors per group were used, and Actin is shown as loading control. ImageJ 
analysis was performed on vector (n=6), 231.shmdm2 (n=4) and 231.shmdmx (n=5) tumor 
samples for MDMX, MDM2, mtp53 protein levels. * represents p<0.05, ** represents p<0.01, 
***represents p<0.001, NS represents non-significant. The p-value was calculated using two-
tailed unpaired t-test. 
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Because we saw a drastic reduction of CTC counts when MDM2 or MDMX was depleted, 
we wondered whether this phenotype correlated with a decrease in the tumor-stromal invasion. 
Therefore we examined the pathological features of the H&E stained primary tumor slides. 
Histopathology analysis revealed that all primary tumors exhibited similar local invasion with 
invasive edge leading to stromal tissues irrespective of MDM2 or MDMX knockdown (Figure 17). 
Cells in all tumors displayed mesenchymal phenotype, suggesting that the local-stromal 




Figure 17. MDA-MB-231 transplants have locally invasive growth irrespective of MDM2 or 
MDMX knockdown.  
H&E staining of one representative image from primary tumors from 231.Vector (blue), 
231.shmdm2 (pink) or 231.shmdmx (green) group at 12.5X magnification (upper panel, scale bar 
1mm) or 200X magnification. (lower panel, scale bar 50 μm). All tumors had a locally invasive 
pattern at the orthotopic transplantation site. T represents Tumor, nm represents normal mammary 





In this chapter we explored the in vitro role of MDM2 in MDA-MB-231 cell proliferation 
as well as migration using both inducible and constitutive knockdown approaches. We showed 
that in contrast to the growth-promoting activity of MDM2 in ER+ breast cancer cells, inducible 
MDM2 knockdown in MDA-MB-231 cells does not provide proliferative advantage to these cells 
(Figure 8). Additionally we demonstrated the ability of MDM2 to promote 2D cell migration 
measured by wound healing assay (Figure 9). This suggests a highly context dependent role of 
MDM2 in breast cancer development. 
Elevated MDMX expression correlates with lymph node metastasis and poor prognosis in 
some cancers (Bao et al., 2016; Zhao et al., 2017). A significant overexpression of mdmx is found 
in patients with claudin-low subtype of breast cancer (Figure 10). Since MDMX and MDM2 
share structural homology and biological functions, we generated constitutive knockdown cell 
lines for both MDM2 and MDMX to better compare the biological outcomes in TNBC 
progression. In agreement with our inducible MDM2 knockdown data, constitutive MDM2 
depletion did not change mtp53 mRNA or protein levels. We extended this finding by introducing 
MDMX knockdown and observed the same results (Figure 11). This is not surprising as MDMX 
lacks E3 ligase activity and does not control p53 abundance alone (Gu et al., 2002; Linares et al., 
2003; Linke et al., 2008). We also showed that MDMX knockdown did not alter MDM2 protein 
or mRNA levels. MDM2 knockdown on the other hand, robustly increased MDMX protein levels 
while the mRNA levels remained unchanged (Figure 11 and 16). This indicates the regulation of 
MDMX occurs at post-transcriptional levels. Since MDM2 functions as an E3 ligase towards 
MDMX (Pan and Chen, 2003), it is likely that MDM2 in this cell line is responsible for the 
degradation of MDMX.  
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It has been reported that MDMX confers a proliferative advantage to breast cancer cells 
harboring mtp53 (Miranda et al., 2017). However we did not observe any change in cell 
proliferation with constitutive MDMX knockdown (Figure 12B). A possible explanation for this 
is the different knockdown strategy used in previously published study. It is documented that Dox 
induces changes in proliferation and metabolic gene expression (Ahler et al., 2013; Fife et al., 
1998). Therefore Dox administration may provide a source for cellular stress and MDMX could 
be critical in sustaining the proliferative and survival capacity of the cells. Although it is worth 
mentioning that in our animal model, we detected a slight but statistically significant smaller 
tumor size during early tumor development in response to MDMX knockdown (Figure 16A). This 
trend persisted but was statistically insignificant at the later stage as well as in the documented 
final sizes (Figure 16A-B). Thus the exact role for MDMX in primary tumor development 
warrants further investigation.  
Finally we assessed and compared the role of MDM2 and MDMX in cell motility in vitro 
and metastasis in vivo. We showed that in keeping with current knowledge, MDM2 promotes 
metastasis and more importantly, MDMX knockdown significantly reduced cell migration, CTCs 
and lung foci formation (Figure 12, 14 and 15). This data agreed with the recent finding on the 
metastasis-promoting function of MDM2 (Hauck et al., 2017). In addition it suggests MDMX 
may also be important in lung colonization of breast cancer cells. To examine whether these is a 
direct relationship between MDMX and lung metastases, tail-vein injection of cancer cells can be 
performed to bypass the initial and intermediate stages of metastasis thus allowing for direct 
testing on the extravasation and colonization ability of cells to the lung. Since we saw that MDM2 
and MDMX knockdown significantly blocked tumor cell intravasation, we expected to observe a 
reduced stromal invasion pattern. Intriguingly the primary tumors exhibited similar invasive 
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properties regardless of MDM2 or MDMX knockdown (Figure 17). We examined the levels of 
several EMT markers including Fibronectin, SNAIL and Vimentin in both cultured cells and 
primary tumor samples and observed no change associated with MDM2 or MDMX knockdown 
(data not shown). Although we cannot exclude the possibility that MDM2 or MDMX induces 
EMT through increasing other EMT associated proteins, it is likely that MDM2 or MDMX 
knockdown mediated CTC blockade also occurs through other mechanisms. A recent finding has 
shown that intravasation can take place within primary tumor core via the intratumoral vascular 
network independent of stromal tissue invasion (Deryugina and Kiosses, 2017). MDM2 has been 
implicated in activating angiogenesis by increasing vegf expression (Zhou et al., 2011). Taken 
together, it is possible that MDM2 or MDMX knockdown decreased the vascular density thus 








MDMX PROMOTES THE TUMOR-ASSOCIATED 
TRANSCRIPTION OF CXCR4 AND PTGS2 
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5.1 Introduction  
MDM2 has been shown to control gene expression by interacting with mRNAs or via 
modulating chromatin landscape. The RING domain of MDM2 not only is critical for its E3 
ligase activity, but also has been proposed to directly bind to mRNA. As such, genes including 
p53, vegf, mycn and slug have been documented to be regulated by MDM2 at the post-
transcriptional level, either by increasing mRNA stability or enhancing its translation (Candeias et 
al., 2008; Gu et al., 2012; Jung et al., 2013; Zhou et al., 2011). These findings strongly imply 
alternative oncogenic functions of MDM2 as a RNA-binding protein.  
In addition to mRNA, we and others have reported that MDM2 interacts with p53 at sites 
of its response elements (Arva et al., 2005; Copson et al., 2006; Rosso et al., 2015). Several other 
studies have highlighted the importance of chromatin-bound MDM2 in attenuating DNA damage 
response, repressing cell differentiation and upregulating genes involved in Serine/Glycine 
biosynthesis and redox homeostasis independently of p53. Chromatin bound MDM2 influences 
these biological processes by directly interacting with the DNA repair complex MRN (Alt et al., 
2005), histone modifying enzyme PRC2 (Wienken et al., 2016; Wienken et al., 2017), and stress-
responsive transcription factors ATF3/4 (Riscal et al., 2016a; Riscal et al., 2016b).  
Although MDM2 has been documented as a gene regulator and a chromatin modifier, 
such functions have not been fully explored for MDMX except its interaction with MRN complex 
(Carrillo et al., 2015). The RING domain interacts with mRNA whereas N-terminal of MDM2 is 
involved in chromatin related functions ((Riscal et al., 2016b; Wienken et al., 2016) and reviewed 
in (Fahraeus and Olivares-Illana, 2014)). Given the strong similarity between MDM2 and MDMX 
in these domains, it is possible MDMX also regulates gene expression. Therefore we evaluated 
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the primary tumor associated transcriptomic changes to identify the novel molecular target(s) of 
MDM2 and MDMX in potentiating metastasis in MDA-MB-231 breast cancer cells.  
5.2 Results 
5.2.1 MDMX knockdown correlates with tumor-associated cxcr4 and ptgs2 expression 
We explored the metastasis targets using a pre-designed RT-PCR microarray card 
screened with RNA prepared from the orthotopic NSG MDA-MB-231.vector, MDA-MB-
231.shmdm2, and MDA-MB-231.shmdmx mouse tumors. The pre-designed human metastasis 
microarrays carry primers to 88 tumor suppressors or oncogenes. We identified a subset of gene 
expression targets associated with MDM2 or MDMX knockdown (Figure 18A and Table 3). The 
targets were assembled into three clusters with fold change thresholds set below 0.5 or above 2. 
The top hits are displayed in a heatmap with the most notably positively associated genes being 
ptgs2 and cxcr4 (Figure 18A). Importantly, cxcr4 and ptgs2 are established as genes that mediate 
organ-specific metastasis in TNBCs (Bos et al., 2009; Kang et al., 2003; Minn et al., 2005; Zhang 
et al., 2009). Cxcr4 encodes a G protein coupled receptor protein (GPCR) that binds to CXCL12 
ligand and is highly expressed in breast cancer patients (Li et al., 2005). Prostaglandin-
endoperoxide synthase PTGS2/COX-2 encoded by ptgs2 is involved in the prostaglandin E2 
pathway and mediates breast cancer progression (Arun and Goss, 2004; Chen et al., 2014). We 
validated this association between ptgs2 and cxcr4 expression and MDM2 or MDMX knockdown 
by performing qRT-PCR from the sets of primary tumor samples. The tissues showed MDMX-
associated 95% down-regulation of cxcr4 transcripts and a trend of (65%) down-regulation of 
ptgs2 (Figure 18B). Both ptgs2 and cxcr4 showed an MDM2-associated reduction but were 




Figure 18. MDMX knockdown in primary tumors reduces mRNA levels of cxcr4.  
(A) Microarray analysis reveals selected tumor metastasis related gene expressions that were 
either up or down regulated in shmdm2 and shmdmx compare to vector control in primary tumor 
tissues. Fold changes were gated either >2 or <0.5. Two tumor samples per group were used for 
the analysis. (B) Total cxcr4 and ptgs2 levels normalized to gapdh from the respective cell lines 
derived primary tumors were determined by quantitative real-time RT-PCR. The bars represent 
mean values and error bars represent standard deviations. The p-value was obtained with two-
tailed unpaired t-test. 
 
To determine whether these genes were directly induced by MDMX or MDM2 in the cell 
lines, we examined the mRNA levels of cxcr4 and ptgs2 in response to constitutive MDMX or 
MDM2 knockdown in regular cell culture. We saw that in comparison to primary tumor tissues, 
cxcr4 and ptgs2 mRNAs were expressed 10-fold lower in 2D cultured cells. Moreover MDMX or 
MDM2 knockdown alone in 2D cell culture system did not alter expression of either genes 
(Figure 19). This suggests MDA-MB-231 cells have a different gene expression profile when 





Figure 19. MDMX or MDM2 does not directly regulate the transcription of cxcr4 and ptgs2.  
The 231.vector, 231.shmdm2 and 231.shmdmx cells grown in regular 2D culture condition were 
lysed for total RNA extraction and cDNA synthesis (n=3). qRT-PCR was carried out and mRNA 
levels for cxcr4 and ptgs2 normalized to gapdh were compared to respective cell lines derived 
primary tumors shown in Figure 18B.  
 
Chromatin-associated MDM2 has been reported to act as a co-factor to support EZH2 
mediated epigenetic silencing marker H3K27 trimethylation thus repressing cxcr4 expression in 
MCF-7 cells (Wienken et al., 2016). In MDA-MB-231 cells we did not detect significant changes 
of cxcr4 in original cell lines with MDM2 knockdown. We wondered whether MDM2 was 
localized differently in these cells. Therefore we performed subcellular fractionation to determine 
the abundance of MDM2 and MDMX in a panel of breast cancer cell lines. We saw that high 
levels of MDM2 on chromatin in both ER+ MCF-7 and T47D cells compared to triple negative 
MDA-MB-231 and MDA-MB-468 breast cancer cells (Figure 20. compare lanes 5&8 to lanes 
6&7). In line with published findings, we observed an increased tumor associated cxcr4 
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expression upon MDM2 knockdown in T47D transplants (data not shown). This is suggestive of 
MDM2 repressing cxcr4 in T47D cells by interacting with EZH2. On the contrary, we saw a 
significant low level of chromatin-bound MDM2 in TNBC lines (Figure 20 compare lanes 6&7 to 
lanes 5&8). Therefore the difference of cxcr4 regulation by MDM2 in the context of T47D and 
MDA-MB-231 cells may be explained in part, by the low levels of MDM2 tethered on the 
chromatin.  
 
Figure 20. Chromatin-bound MDM2 is present at low levels in triple negative compared to 
ER+ breast cancer cell lines.  
MCF-7, T47D, MDA-MB-231 and MDA-MB-468 breast cancer cells were subject to subcellular 
fractionation. 50 ug of cytosolic or chromatin fraction lysates from corresponding cell lines were 
separated in a 10% SDS-PAGE. Actin was used as cytosolic fraction normalizer and Fibrillarin 
served as chromatin fraction normalizer. 
 
5.3 Discussion 
Using transcriptomic analysis we identified novel tumor-associated target genes of MDM2 
and MDMX in mediating MDA-MB-231 metastasis. Our initial screen identified a subset of 
genes that were significantly associated with MDM2 or MDMX knockdown in primary tumors 
(Figure 18A and Table 3). Further validation confirmed cxcr4 as a potential target gene 
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upregulated by MDMX in MDA-MB-231 tumors (Figure 18B). Elevated CXCR4 expression has 
been documented in more than 23 different types of cancers with various origins and has been 
shown as a poor prognostic biomarker (Zhao et al., 2015). Inhibition of CXCR4 leads to 
significantly less metastatic burden in mouse models (Balkwill, 2004; Kang et al., 2003; Muller et 
al., 2001) and new treatments targeting this pathway in TNBC are having some success (Pernas et 
al., 2018). In addition to its well-characterized role in directing breast cancer bone metastasis 
(Kang et al., 2003; Zhang et al., 2009), there is some evidence for CXCR4 mediated intravasation 
during metastasis. Forced expression of CXCR4 in rat breast cancer cell line increases cancer cell 
motility and intravasation in vivo (Hernandez et al., 2011), and hypoxia-induced endothelial 
CXCL12 secretion has been shown to stimulate transendothelial migration of tumor cells 
expressing CXCR4 (Jin et al., 2012). Thus our data suggests that tumor associated down-
regulation of cxcr4 may play a role in the observed decrease in CTCs mediated by MDMX 
knockdown. 
When we validated our finding in cell culture conditions, the low levels of cxcr4 or ptgs2 
expression indicates a vast difference of gene expressions incurs when cells were growing in 
different environments (Figure 19). This is not unexpected as studies using 3D culture systems 
that mimic in vivo environment have demonstrated differential morphologies, gene expressions 
and drug sensitivities comparing to monolayered cell culture ((Kenny et al., 2007) and reviewed 
in (Edmondson et al., 2014; Kim et al., 2004)). Furthermore, a study on primary xenograft model 
of lung cancer specimen reveals differential gene expression when cells are implanted in mice 
compared to cells passaged in culture (Daniel et al., 2009). Nonetheless, the fact that we did not 
detect any transcriptional alteration for these genes in MDM2 or MDMX knockdown in cell 
culture (Figure 19) suggests neither molecule by itself directly regulates their expressions.  
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It is worth noting that the complexity of cancer extends beyond the genetic and epigenetic 
alterations of cancer cells alone. The tumor microenvironment (TME) also plays an integral part 
to foster the development and progression of cancer. The TME is enriched in secreted factors 
produced by both tumor cells and stromal cell populations. The production of transforming 
growth factor-β (TGF-β), stromal derived factor (SDF)-1/CXCL12, and hepatocyte growth factor 
(HGF) in breast cancer associated fibroblasts has been show to fuel tumor cell growth, motility 
and metastasis via paracrine signaling ((Jedeszko et al., 2009; Orimo et al., 2005) and reviewed in 
(Calon et al., 2014; Place et al., 2011)). In addition to the secreted proteins, hypoxia and 
inflammation in the TME account for significant changes of gene expression (reviewed in 
(Grivennikov et al., 2010; Semenza, 2016)). Our data clearly demonstrated the context dependent 
gene expression prolife under different growth conditions. It also indicates the activation of 
signaling events in the TME contributes to the induction of cxcr4 and ptgs2 and MDMX is 
required to sustain such induction.  
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The table below lists identified genes corresponding to the Figure 18 heatmap with a brief 
description and function annotation (Table 3). 
 











Gene Description and Function 
cxcr4 1 0.05 0.02 Chemokine receptor for CXCL12, highly expressed 
in breast cancer cells 
ptgs2 1 0.09 0.21 Encodes Cyclooxygenase-2 (COX-2), Prostaglandin 
biosynthesis, implicated in breast cancer lung and 
brain metastases 
mmp1 1 0.11 0.50 Matrix Metalloproteinase 1, breaks down the 
interstitial collagens, together with ADAMTS1 
predicts breast cancer bone metastasis 
vegfa 1 0.59 0.46 Vascular Endothelial Growth Factor A, induces 
proliferation and migration of vascular endothelial 
cells 
wisp1 1 0.47 0.53 WNT1 Inducible Signaling Pathway Protein 1, 
downstream regulator in the Wnt pathway, 
associated with cell survival. Attenuates p53-
mediated apoptosis in response to DNA damage 
through activation of AKT kinase.  
itgb3 1 0.81 0.44 Integrin Subunit Beta 3. Associates with Integrin 
α2b or α5. Receptor for fibronectin, laminin, MMP2 
s100a4 1 2.03 0.81 S100 Calcium Binding Protein A4, belongs to S100 
protein family, functions in motility, invasion, and 
tubulin polymerization 
mtss1 1 2.3 1.78 Metastasis suppressor protein 1, related to 
Hedgehog pathway and cytoskeletal signaling, 
binds to Actin 
timp4 1 3.81 2.11 TIMP Metallopeptidase Inhibitor 4, known to act on 












Figure 21. Model describing context dependent biological outcomes of MDM2 and MDMX 
in T47D (ER+) and MDA-MB-231 (TNBC) breast cancer cells.  
 
In this thesis we stratified the differential biological outcomes of endogenously 
overexpressed MDM2 in T47D versus MDA-MB-231 breast cancer cells (Figure 21). We showed 
that estrogen activated MDM2 promotes in vivo tumor growth of ER+ T47D breast cancer cells 
containing mtp53 without increasing tumor invasive properties, and this is supported by 
unchanged E-Cadherin protein levels both in vitro and in vivo.  
In MDA-MB-231 cells MDM2 did not increase proliferation but provoked cell motility in 
vitro, CTCs and lung foci formation in vivo. Furthermore our study revealed an important role for 
MDMX in promoting cell migration and provided the first in vivo evidence for MDMX-mediated 
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metastasis. Microarray analysis identified a subset of metastasis related genes that were up or 
down regulated by MDM2 and MDMX. and ptgs2 expression. Although the reduction of cxcr4 
was not a direct result of MDMX knockdown in cell culture, we observed a strong positive 
correlation between MDMX and tumor-associated cxcr4 expression. This indicates additional 
signaling pathways are involved in MDMX-mediated breast cancer metastasis in primary tumors. 
The MDM2-mediated metastatic phenotype was not achieved by the upregulation of tumor-
associated cxcr4, suggesting MDM2 enables metastasis through other molecular mechanisms.  
6.2 Future directions and preliminary data 
MDM2 has been shown to promote in vivo metastasis in some TNBC cells (Hauck et al., 
2017). In our study, we showed that MDMX potently increases CTCs and enhances tumor-
associated cxcr4 expression. These findings could be tested in multiple TNBC cell lines to 
determine cell-type specific effects and to characterize how cell context dictates biological 
outcomes. Furthermore the underlying molecular mechanism by which MDMX contributes to 
breast cancer metastasis warrants further investigation. We carried out a number of experiments 
that helped to suggest future work. Some of these results are described below along with possible 
future experiments. These are highly varied in nature and are not designed to follow one key 
theme. 
6.2.1 Investigating the molecular mechanism by which MDMX promotes metastasis 
6.2.1.1 Determine the role of MDMX in cxcr4 activation in response to hypoxia 
In Chapter 5, we have shown that the expressions of cxcr4 and ptgs2 in primary tumors 
were significantly upregulated compared to that in monolayer cell culture (Figure 19). This 
implies key signaling pathways are turned on and MDMX may play a role in maintaining the 
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signaling transduction thereby increases the metastatic potential of tumor cells. One of the major 
factors for solid tumor progression is hypoxia. In response to oxygen tension, breast cancer cells 
stabilize and activate hypoxia inducible factor-1 (HIF-1). The induction of a variety of gene 
expression by HIF-1 leads to extracellular matrix remodeling (Goggins et al., 2018), cell invasion 
(Hoffmann et al., 2018) and the secretion of pro-angiogenic factor VEGF ((Forsythe et al., 1996) 
and reviewed in (Ell and Kang, 2013)). High levels of HIF-1 correlates with poor prognosis and 
has been implicated in breast cancer metastasis (Lu et al., 2010). The activation of HIF-1α have 
been shown to induce cxcr4 (Dunn et al., 2009; Phillips et al., 2005; Schioppa et al., 2003; Staller 
et al., 2003). MDM2 exerts context specific regulation towards HIF-1α. Both MDM2-mediated 
HIF-1α degradation and stabilization have been reported (Joshi et al., 2014; Nieminen et al., 
2005). Whether MDMX can activate this pathway is unknown. To examine this potential 
relationship between MDMX and HIF pathway, we can culture the cells in hypoxic condition to 
stimulate the activation of HIF pathway and assess first if cxcr4 expression can be induced by 
hypoxia, and whether HIF-1α protein expression or activity is reduced by MDMX knockdown. 
The overall expression of HIF-1α can be analyzed by whole cell protein levels, while chromatin 
fractionation can be used to determine if MDMX facilitates the nuclear entry of HIF-1α. 
Moreover chromatin immunoprecipitation can help identify whether HIF-1α recruitment to the 
cxcr4 promotor is decreased with MDMX knockdown. 
6.2.1.2 Examine the role of MDM2 and MDMX in NF-κB target gene expression 
Chronic inflammation has long been associated with increased breast cancer recurrence 
and is well known for its ability to supply growth, survival, proangiogenic and metastasis-
promoting factors that are indispensable for tumor progression and metastasis (DeNardo et al., 
2010; Grivennikov et al., 2010; Karnoub et al., 2007). Cancer cells induce inflammation through 
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aberrant expression and constitutive activation of nuclear factor-kappaB (NF-κB) family of 
transcription factors (reviewed in (Colotta et al., 2009; Grivennikov et al., 2010)). The NF-κB 
signaling regulates mammary epithelial proliferation, tissue architecture and ductal tree branching 
during normal mammary gland development (Cao et al., 2001; Geymayer and Doppler, 2000). In 
breast carcinoma, high levels of nuclear NF-κB have been documented in both cancer cell lines 
and tumor tissues samples (Biswas et al., 2004; Lerebours et al., 2008; Nakshatri et al., 1997; 
Sovak et al., 1997). Over-expression and constitutive activation of NF-κB subunits are associated 
with cancer progression (Huber et al., 2004). Several mouse model studies have demonstrated that 
the activity of NF-κB is necessary to maintain an invasive phenotype in breast cancer (Huber et 
al., 2004; Shin et al., 2006; Wang et al., 2007). The extracellular signal activated NF-κB also 
plays a role in inducing cxcr4 (Helbig et al., 2003; Zhi et al., 2015).  
Forced MDM2 expression reportedly induces the expression and activity NF-κB subunits 
independently of p53 through 1) inducing the transcription of p65 by binding to the SP-1 site in 
its promoter region (Gu, 2002); and 2) increasing the expression of p100, although the mechanism 
is unclear (Vaughan et al., 2011). We showed that similar to cxcr4, the mRNA levels of ptgs2 in 
primary tumors were highly elevated compared to 2D culture condition. This induction of ptgs2  
can be linked with an inflamed tumor microenvironment that leads to the activation of NF-κB 
signaling (Pahl, 1999).  Our endogenous MDM2 knockdown in MDA-MB-231 transplants did not 
yield significant changes in tumor-associated ptgs2 expression. However we cannot exclude the 
ability of MDM2 in regulating a subset of NF-κB target genes. Moreover, MDMX knockdown 
showed a significant decrease of cxcr4 transcripts and trend of reduction in tumor-associated 
ptgs2 mRNA, suggesting MDMX might have some functions in NF-κB pathway. 
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To evaluate if MDM2 or MDMX promotes NF-κB signaling activation, we carried out 
PCR analysis on the pre-designed human NF-κB pathway microarray plate which contains 92 
assays to NF-κB associated genes as well as 4 endogenous control genes. The same cDNA 
samples that were screened for from corresponding primary tumors were used, and target 
candidates were filtered based on fold exchange either >2 or <0.5 comparing to vector control 
group. We saw that the majority of genes that past our filter were down-regulated with either 
MDMX or MDM2 depletion (Table 4). Many of these genes are involved in promoting cell 
adhesion, migration, angiogenesis and subsequent metastasis in cancers. Notably ccl2, enpp2 and 
icam1 were significantly down-regulated by MDMX knockdown (~70%) and moderately 
inhibited by MDM2 depletion (~45% except enpp2).  
The CCL2-CCR2 axis is closely connected with cancer progression and metastasis. High 
levels of CCL2 correlate with a poor survival in patients with breast, colorectal and prostate 
cancer due to high incidence of early relapse (Lu et al., 2006; Ueno et al., 2000; Yoshidome et al., 
2009). Sun and colleagues recently have shown that epithelial cell-specific expression of CCL2 
induces chronic inflammation in mammary gland thus leading to an increased susceptibility of 
mammary cancer in Mmtv-Ccl2 mice (Sun et al., 2017). This provides direct evidence on CCL-2 
driven breast cancer risk.   
A few cell adhesion molecules also came up in our initial screening. ICAM-1 is a well-
established biomarker for inflammation. Recently ICAM-1 (along with CCL2 and VCAM-1) is 
identified as one of the selectively highly expressed genes in a panel of TNBC cells but not non-
TNBC and normal mammary epithelial cells. Administration of antibody conjugated iron oxide 
nanoparticles (ICAM-IONPs) significantly blocks the invasion of TNBC, providing some 
evidence on the role of ICAM-1 in promoting TNBC metastasis (Guo et al., 2014). The VCAM1 
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(Vascular Cell Adhesion Molecule 1)-expressing cells are found to have enhanced survival 
mediated by Ezrin-PI3K/Akt pathway via metastasis-associated macrophage binding (Chen et al., 
2011).  




In addition to validate these potential targets in our tumor samples, it is important to 
examine whether there is a direct relationship between MDM2 and/or MDMX and expression of 
these genes. It has been shown that MDM2 acts as a co-activator downstream of Toll-like 
receptor induced NF-κB signaling independently of p53, and this induction of NF-κB target genes 









Gene Description and Function 
ccl2 1 0.43 0.24 C-C Motif Chemokine Ligand 2, part of CCL2-
CCR2 axis, promotes breast cancer cell 
migration, angiogenesis and subsequent lung 
metastasis 
enpp2 1 0.24 0.26 Ectonucleotide Pyrophosphatase/ 
Phosphodiesterase 2, catalyzes production of 
lysophosphatidic acid (LPA), stimulates motility 
and angiogenesis of tumor cells 
icam1 1 0.49 0.34 Intercellular Adhesion Molecule 1, associated 
with breast cancer cell invasion 
il10 1 0.3 0.48 Interleukin 10, controversial roles in cancer 
development, implicated in both tumor growth-
promoting and angiogenesis/metastasis 
suppression 
il-1a 1 0.35 0.58 Interleukin-1 alpha, promotes tumor growth 
tnfsf11 1 0.49 0.06 RANKL, TNF Superfamily Member 11, involved 
in osteoclast differentiation and activation 
vcam1 1 0.59 0.44 Vascular Cell Adhesion Molecule 1, aberrantly 
expressed in breast cancer cells, mediates pro-
metastatic tumor stromal interactions 
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of MDM2 and MDMX by stimulating the cells with LPS in regular cell culture and assess 1) 
whether the expression of potential target genes can be induced; 2) whether knockdown of 
MDM2 or MDMX knockdown can decrease their transcriptions; 3) whether MDM2 or MDMX 
facilitates NF-κB DNA-binding. This will directly address if the changes of tumor-associated NF-
κB target gene expression is a result of MDM2 and/or MDMX functions downstream of NF-κB 
signaling pathway activation. 
6.2.1.3 Examine the roles of MDM2 and MDMX on angiogenesis related gene expression 
In this study we discovered strong associations between MDM2/MDMX and the CTC 
counts in mice. Interestingly in our orthotopic mouse model, MDA-MB-231 derived primary 
tumor invasiveness remained unchanged irrespective of MDM2 or MDMX depletion. The fact 
that we were able to detect changes in the number of CTCs in the circulatory system suggests that 
MDM2 and MDMX may promote the intravasation of metastasis. Most metastases are a result of 
dissemination via circulatory systems. Cancer cells are known to exploit neovessel networks as a 
mean to disseminate and arise in distant organs (reviewed in (Bielenberg and Zetter, 2015)). Thus 
it is important to examine whether MDM2 or MDMX promotes intravasation by either enhancing 
the transcription of angiogenic factors or inhibiting the production of angiostatic factors. 
A positive association between MDM2 and angiogenesis factors in primary breast cancer 
patients has been reported (Inada et al., 1996). Additionally in prostate cancer cells MDM2 
overexpression correlates with angiogenesis related gene expression (Venkatesan et al., 2018). 
Mechanistically MDM2 stabilizes vegf transcript (Zhou et al., 2011), and dual inhibition of 
MDM2 and VEGF leads to reduced angiogenesis and metastasis in neuroblastoma and human 
breast cancer (Patterson et al., 2011; Xiong et al., 2014). Hauck and colleagues have also reported 
a correlation between MDM2 and VEGF expression in TNBC cells and knockdown of MDM2 
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associates with a lower percentage of vessel formation within primary tumors (Hauck et al., 2017). 
Our tumor metastasis microarray reveals a 41% reduction of the vegfa transcripts with MDM2 
knockdown, and a 54% decrease with MDMX knockdown (Figure 18A and Table 3). Taken 
together, we hypothesized that MDM2 and MDMX promote angiogenesis that leads to enhanced 
intravasation in MDA-MB-231 primary tumors.  
To determine whether there is a global impact of MDM2 and/or MDMX in tumor-
associated angiogenesis, we performed transcriptomic analysis using a pre-designed angiogenesis 
array plate. cDNAs from three tumor samples in either vector control group or shmdmx group, 
and two tumor samples in shmdm2 group were analyzed. Fold change threshold was set either 
greater than 2 or less than 0.5. Among the 88 genes screened we found that the transcript levels of 
6 genes were altered (Table 5) with either MDM2 or MDMX knockdown. 
Our preliminary screening data suggests that neither MDMX nor MDM2 had a profound 
impact on genes directly involved in angiogenesis from primary tumors. Interestingly most of the 
genes are differentially regulated by MDM2 and MDMX (Table 5 All genes except pf4). This 
implies possible distinct functions of MDM2 and MDMX in tumor-associated angiogenesis. 
Curiously, MDMX knockdown tumors appear to have a more consistent positive association with 












Table 5. Select tumor-associated targets of MDM2 and MDMX in angiogenesis microarray 
screening 
 
While research on SEMA3F is limited, the secreted PF4/CXCL4 ligand is known to  be 
involved in numerous physiological processes such as hematopoiesis inhibition, platelet 
coagulation, leukocyte differentiation and activation (reviewed in (Vandercappellen et al., 2011)). 
PF4/CXCL4 is an angiostatic chemokine that inhibits binding of growth factors such as FGF and 
VEGF to cells. Recently it has been shown that PF4/CXCL4 knockout mice with orthotopic 
implantation of B16F10 murine melanoma cells display increased tumor growth and lung 
metastases, indicating an anti-metastasis effect of PF4/CXCL4 in melanoma (Jian et al., 2017). 
Furthermore, PF4/CXCL4 expression negatively correlates with cancer stage and positively 
associates with survival in colon, lung and breast cancer patients, providing clinical significance 









Gene Description and Function 
adamts1 1 1.7 0.11 A Disintegrin And Metalloproteinase with 
Thrombospondin Motifs 1. Actives 
metalloprotease 
serpinf1 1 0.39 0.65 Serpin Family F Member 1, secreted and inhibits 
angiogenesis 
csf3 1 0.56 5.13 Colony Stimulating Factor 3, cytokine that 
controls the production, differentiation, and 
function of granulocytes 
sema3f 1 0.98 2.46 Semaphorin 3F, has repulsing activity on breast 
cancer cell migration, inhibits cell proliferation 
and survival 
tnfsf15 1 2.04 0.33 TNF Superfamily Member 15, can activate NF-
kappaB and MAP kinases, acts as an autocrine 
factor to induce apoptosis in endothelial cells 
pf4 1 2.17 2.21 Platelet Factor 4, also known as CXCL4, CXC 
chemokine family member, functions to inhibit 
hematopoiesis  
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expressing PF4/CXCL4 has biological relevance to cancer development and progression remains 
to be determined.  
Aside from PF4, we also identified tumor associated adamts1 as a promising target 
upregulated by MDMX. Metalloproteinases MMP1 and ADAMTS1 are part of the key gene 
signature that predicts breast cancer metastasis to bone (Kang et al., 2003). Mechanistically, the 
combined actions of MMP1 and ADAMTS1 shed EGF (Epidermal Growth Factor)-like ligand 
from the tumor cell surface which leads to osteoclast differentiation and subsequent bone 
destruction (Lu et al., 2009). Here we identified both molecules as potential MDMX targets 
(Figure 18A, Table 3 and Table 5), indicating tumors with MDMX knockdown may have less 
metastatic potential in homing in bone. This hypothesis could be tested by analyzing bone lesions 
using X-Ray. To confirm the lesions are a result of tumor cell dissemination, we can trace the 
cells residing in bone by GFP visualization.  
In addition to microarray target gene validation, it is also important to assess directly if the 
formation of tumor associated neovasculature is reduced in response to MDMX knockdown. One 
way to test this is to stain for endothelial cell marker CD31 in primary tumors and quantify the 
neo-vessel formation within the tumors. This would allow us to address whether MDMX is able 
to induce tumor angiogenesis.  
6.2.2 Determine the role of MDMX in estrogen-mediated T47D cell proliferation 
In luminal A&B subtypes of breast cancer which largely maintain ER expression and gain 
of MDMX occurs at ~30% in patients. In addition to its ability to repress wtp53, either by itself or 
co-opt with MDM2, MDMX has been shown to elicit p53-independent activities on promoting 
cell cycle progression (Jin et al., 2008; Miranda et al., 2017; Zhang et al., 2015). Furthermore 
estrogen has been shown to induce p53-independent MDMX expression via activation of ER 
77  
(Swetzig et al., 2016). This evidence suggests MDMX contributes to ER+ breast cancer 
development. In order to further understand the biological process MDMX participates in, we 
generated constitutive MDMX knockdown in T47D breast cancer cells and hypothesized that 
MDMX provides proliferative advantage to these cells in response to long-term estrogen 
treatment. 
 
Figure 22. Stable MDMX knockdown does not change estrogen-mediated T47D cell 
proliferation.  
(A) T47D cells with MLP control vector or shmdmx (13023) were generated using retrovirus 
infection. Cells were selected with 5 µg/ml puromycin for 7 days. Western Blot analysis showing 
protein levels of MDMX, MDM2, and mtp53 in Vector control and shmdmx cells. Actin serves as 
loading control. (B) Number of cells was determined by cell counting. 50,000 cells were seeded at 
the beginning of experiment. Cells were treated with or without 10 nM estrogen for 5 days. Bar 
graph represents average of cell number from three independent experiments. p value was 
obtained by two-tailed student t-test. *** represents p<0.005. NS represents non-significant. (C) 
Representative image from Western Blot analysis for MDMX protein expression in response to 
long-term estrogen treatment. Actin served as loading control. 
 
We first determined whether MDMX knockdown in T47D cells altered expression of 
MDM2 and/or mtp53. As expected constitutive MDMX knockdown did not change MDM2 or 
mtp53 protein expression (Figure 22A). Five days of estrogen treatment increased cell 
proliferation and MDMX levels (Figure 22B and 22C compare lane 1&2 and lane 3&4). However 
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MDMX knockdown did not inhibit proliferation with or without estrogen (Figure 22B). This data 
suggests that MDMX is not involved in estrogen mediated T47D cell proliferation. It has been 
shown that ER induced MDMX can in turn form complex with MDM2, ER and wtp53. While 
MDM2 has been shown to regulate ERα and ERβ (Duong et al., 2007; Sanchez et al., 2013; 
Swetzig et al., 2016), little is known about the role of MDMX in this relationship. It would be 
interesting to determine whether MDMX forms a complex with ER in mtp53 expressing cells and 
whether this complex formation requires MDM2.  
6.2.3 Determine the role of MDM2-C in breast cancer 
The mdm2-c transcript lacks exons 5 through 9 and encodes a protein product missing 
most of the p53-binding domain, NLS, NES and partial acidic domain. We have previously 
generated and validated an MDM2-C specific polyclonal antibody that recognizes the peptide 
sequence encoded from the exon 4 and 10 splice junction. Using this antibody, we successfully 
detect high levels of MDM2-C expression in different cancer cell lines with mdm2 SNP309, as 
well as in liposarcoma and breast carcinoma tissues (Okoro et al., 2013). Ectopic expression of 
MDM2-C reveals that MDM2-C neither elicits degradation of wtp53, nor represses wtp53 
transcriptional activity. Additionally, MDM2-C is able to promote colony formation when over-
expressed in p53 null cancer cells (Okoro et al., 2013). This data suggests that MDM2-C exerts 
tumorigenic functions that do not require the inhibition of p53.  
To better understand the functions of this highly expressed MDM2-C isoform, we 
generated mouse monoclonal antibody against the previously published oligopeptide (Figure 
23A). We assessed the specificity of the antibody by Western Blot using in vitro 
transcribed/translated (IVT) MDM2-C and full length MDM2 (MDM2-FL) proteins from HeLa 
cell extract. The protein products were probed with 4B11, SMP-14 and 7C7 antibodies.  
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4B11 recognizes the C-terminus of MDM2, therefore it detects both MDM2-FL and 
MDM2-C. Consistent with previously published finding, the observed MDM2-C isoform co-
migrates with MDM2-FL (Okoro et al., 2013). Both proteins are detected around 98 kDa, higher 
than their predicted molecular sizes of 36 kDa and 55 kDa respectively (Figure 23B top 4B11 
panel).  
The large central acidic domain has been attributed to the slow mobility of MDM2 
proteins (Chen et al., 1993). The epitope of SMP-14 lies in the MDM2 central acidic domain 
which is encoded by exon 8, thus only recognizes MDM2-FL but not MDM2-C (Figure 23B 
bottom SMP-14 panel). Another band at ~70 kDa is also detected in in vitro translated MDM2-FL 
lane (Figure 23B lane 2) and has previously been identified as a cleaved product of MDM2-FL at 
C-terminus by Caspase 3 (Pochampally et al., 1998). It is possible that when translated in vitro, 
this protein is post-translationally modified by endogenous factors present in the cell extract, 
resulting in a cleaved form of MDM2-FL. The 7C7 clone recognizes only MDM2-C and not 
MDM2-FL above 98 kDa (Figure 23B middle 7C7 panel), demonstrating a strong specificity to 





Figure 23. MDM2-C is specifically detected by 7C7 monoclonal antibody and is localized 
mainly in the cytoplasmic compartment of breast cancer cells.  
(A) Schematic of MDM2-FL and MDM2-C. The MDM2-C specific monoclonal antibody was 
raised against peptide sequence expanding exon 4/10 junction (GCTYTMKEDLDAGVS). (B) In 
vitro transcribed/translated lysate containing empty Vector, MDM2-FL or MDM2-C was resolved 
in 10% SDS-PAGE and probed with 4B11, 7C7 and SMP-14 antibodies. (C) Cellular localization 
of MDM2-C in breast cancer cell T47D and MDA-MB-231 was assessed by Immunoflouresence. 
A representative image showing a single slice from z-stack of cells. Red signal indicates MDM2 
or MDM2-C. DAPI (blue signal) stains cell nucleus. Images were captured by Nikon A1 
microscope under 60X magnification. Boxes depict selected cells in the field that were further 
magnified. All LUTs per staining condition were the same. 
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We previously reported MDM2-C localizes in distinct foci in both cytoplasmic and 
nuclear components in T47D cells using a polyclonal antibody to MDM2-C (Okoro et al., 2013). 
Here using the newly developed monoclonal antibody against MDM2-C, we compared cellular 
localization of endogenously expressed MDM2-C with overall MDM2 localization in T47D and 
MDA-MB-231 cells by immunofluorescence assay. IF2 antibody, which recognizes N-terminus 
of MDM2, presented signal in both cytoplasmic and nuclear compartments of the cells (Figure 
23C top panel). MDM2 proteins that retain the central acidic domain were detected in the nucleus 
of both cell lines using SMP-14 antibody (Figure 23C, third panel). MDM2-C on the other hand, 
was observed primarily in the cytoplasm for both cell lines. This is expected as MDM2-C does 
not contain NLS or NES (Figure 23A). Taken together our results indicate that the newly 
generated monoclonal antibody specifically recognizes the MDM2-C isoform, and this isoform is 
localized mainly in cytoplasm in both ER-positive and triple negative breast cancer cells.  
It has been reported that MDM2 isoforms, namely A and B which lack the nuclear 
localization sequence, localizes primarily in the cytoplasmic component in the cell. They function 
by binding to MDM2-FL to inhibit its E3 ligase activity towards wtp53 (Evans et al., 2001; 
Schuster et al., 2007). Moreover, MDM2-B promotes GOF mtp53 accumulation by binding to 
MDM2-FL, thus leading to enhanced tumorigenesis and metastasis (Zheng et al., 2013). Because 
MDM2-C has an intact C-terminus, it is therefore conceivable that MDM2-C exerts similar 
activity towards MDM2-FL. This potential function of MDM2-C should be carefully examined 
with respect to different p53 status.  
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